WO2020073974A1 - Agonistes du récepteur des hormones thyroïdiennes - Google Patents

Agonistes du récepteur des hormones thyroïdiennes Download PDF

Info

Publication number
WO2020073974A1
WO2020073974A1 PCT/CN2019/110494 CN2019110494W WO2020073974A1 WO 2020073974 A1 WO2020073974 A1 WO 2020073974A1 CN 2019110494 W CN2019110494 W CN 2019110494W WO 2020073974 A1 WO2020073974 A1 WO 2020073974A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
alkyl
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/CN2019/110494
Other languages
English (en)
Inventor
Xing DAI
Yaolin Wang
Yueheng Jiang
Yanqin Liu
Zixing HAN
Zhenwu Wang
Liangshan TAO
Zhe SHI
Original Assignee
Inventisbio Shanghai Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventisbio Shanghai Ltd. filed Critical Inventisbio Shanghai Ltd.
Priority to KR1020217013711A priority Critical patent/KR20210076932A/ko
Priority to CN201980061525.7A priority patent/CN112739692A/zh
Priority to US17/284,149 priority patent/US20210355110A1/en
Priority to CA3113373A priority patent/CA3113373A1/fr
Priority to AU2019359141A priority patent/AU2019359141A1/en
Priority to EP19871569.0A priority patent/EP3864013A4/fr
Priority to JP2021519839A priority patent/JP2022504706A/ja
Publication of WO2020073974A1 publication Critical patent/WO2020073974A1/fr
Priority to IL282076A priority patent/IL282076A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2

Definitions

  • the present invention relates to novel thyroid hormone receptor agonists, pharmaceutical compositions, methods of preparing and methods of using the same, for example, for treating diseases or disorders such as nonalcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
  • Thyroid hormone plays a critical role in the human endocrine system and controls the energy metabolism through regulating the protein synthesis, carbohydrate and fat metabolism in liver, skeletal muscle and adipose tissue.
  • TH affects cardiovascular, bone and renal functions.
  • the activities of TH are mediated through its binding to thyroid hormones receptors (TRs) , which include both isoforms of TR ⁇ and TR ⁇ .
  • TR ⁇ is primarily expressed in the brain and heart and to a lesser extent in kidney, skeletal muscle, lungs, whereas TR ⁇ is predominantly expressed in the liver, kidneys and at lower levels in brain, heart, thyroid, skeletal muscle, lungs, and spleen. Therefore, TR ⁇ mainly affects the heart function, whereas TR ⁇ controls carbohydrate and lipid metabolism in the liver.
  • TRs thyroid hormone response elements
  • Non-alcoholic fatty liver disease is a global epidemic with an incidence of 30%or more among adults in both developed and developing countries.
  • NAFLD is considered to be a hepatic manifestation of the metabolic syndrome and is closely associated with the development of other metabolic risk factors such as type 2 diabetes mellitus, hyperlipidemia and coronary artery disease.
  • NAFLD represents a spectrum of liver diseases that include excessive accumulation of lipids in the hepatocytes, which is initially benign (hepatosteatosis) but progresses to a more advanced stage with inflammation (non-alcoholic steatohepatitis, NASH) and culminates in fibrosis accompanied by increased inflammation, apoptosis and scarring of liver tissue (cirrhosis) .
  • Patients with cirrhosis eventually progress to hepatocellular carcinoma (HCC) . Therefore, patients with NAFLD and/or NASH have an increased risk of developing HCC later in life.
  • HCC hepatocellular carcinoma
  • the present invention provides novel TR agonists, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds, for example, for the treatment of a disease or disorder modulated by TR agonists, such as a non-alcoholic fatty liver disease and/or NASH.
  • TR agonists such as a non-alcoholic fatty liver disease and/or NASH.
  • novel TR agonists having Formula I, Formula II, or Formula III, or a pharmaceutically acceptable salt thereof:
  • the compound can have a Formula I-1, Formula I-2, Formula I-3, Formula I-4, Formula II-1, Formula III-1, Formula III-2, Formula III-3, Formula III-4, Formula III-1A, Formula III-2A, Formula III-3A, Formula III-4A, Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, as defined herein.
  • the compound can be any one of compounds 1-99.
  • Certain embodiments of the present disclosure are directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, as defined herein, or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition described herein can be formulated for different routes of administration, such as oral administration, parenteral administration, or inhalation etc.
  • Certain embodiments of the present disclosure are directed to a method of treating a disease or disorder associated with TR agonist, such as a non-alcoholic fatty liver disease.
  • the method comprises administering to the subject in need thereof a therapeutically effective amount of a compound of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof, as defined herein.
  • Formula I e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4
  • Formula II e.g., Formula II-1
  • Formula III e.g., Formula III-1, Formula III-2, Formula III-3
  • the administering comprises administration via oral administration, parenteral administration or inhalation.
  • diseases or disorders suitable to be treated with the methods described herein include obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic steatohepatitis, fatty liver, non-alcoholic fatty liver disease, bone disease, thyroid axis alteration, atherosclerosis, a cardiovascular disorder, tachycardia, hyperkinetic behavior, hypothyroidism, goiter, attention deficit hyperactivity disorder, learning disabilities, mental retardation, hearing loss, delayed bone age, neurologic or psychiatric disease, thyroid cancer, and combinations thereof.
  • TR agonists have shown significant promise in the treatment of hypercholesterolemia, hepatic steatosis, and weight loss.
  • these non-selective TR agonists have been associated with adverse action on heart, bone and cartilage. Therefore, more selective and specific agents targeting TH signaling pathways, based on improved mechanistic understanding, will be needed to effectively and selectively target metabolic diseases.
  • MGL-3196 was reported to be a liver-targeted thyroid hormone receptor-beta agonist with certain selectivity over TR-alpha. MGL-3196 was also found to be useful for lowering lipid content in clinical trials. See e.g., Atherosclerosis 230: 373-380 (2013) . Structurally, MGL-3196 is a pyridazinone compound with an azauracil ring, which mimics the natural ligand triiodothyronine (T3) . Limited structural activity relationship (SAR) was published for pyridazinone compounds similar to MGL-3196. J.
  • the disclosed SAR indicates that the optimal substituent on the pyridazinone ring is isopropyl, and the optimal substituent for the azauracil unit is CN, which enhances selectivity over TR alpha.
  • the center phenyl ring is typically substituted with two chlorine groups.
  • the present inventors unexpected found that the CN group on the azauracil ring can be replaced with a hydrophobic group, such as an alkyl, without diminishing its selectivity over TR alpha. Further, such replacement also provided compounds with minimal cellular shift from the receptor binding assay, which means that the observed EC 50 for a cell-based assay is similar to that observed for the receptor binding assay (see details in the Examples section) .
  • the present invention is also based in part on the unexpected discovery that the reported optimal isopropyl group can be modified into various optionally substituted alkyl, cycloalkyl, phenyl, or heterocyclyl group, and the resulted compounds can not only maintain efficacy for TR beta, but in some cases, with improved efficacy and/or with much diminished TR alpha activity. Thus, such modifications can reduce side effects associated with undesired TR alpha activity, for example, in organs such as the heart. Further, in various embodiments, the present inventors found that the center phenyl ring substitution, which is typically a 2, 6-dichlorophenyl, can be modified to achieve higher TR beta potency and/or better selectivity over TR alpha. Additionally, representative compounds of the present disclosure also show enhanced stability in the microsomal stability study, which suggests better pharmacokinetic profile over MGL-3196. Accordingly, in various embodiments, the present invention provides novel compounds containing any one or more of these modifications.
  • the present invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof:
  • R 2 is an optionally substituted alkyl, an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; or R 2 is -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , wherein each of the C 1-6 alkyl is independently selected and optionally substituted,
  • A is O, CH 2 , S, SO or SO 2 ,
  • R 3 is hydrogen or an optionally substituted alkyl
  • R 100 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • R 4 is hydrogen, -CN, -COOH, optionally substituted alkyl (e.g., optionally substituted C 1- 6 alkyl) , or optionally substituted carbocyclyl (e.g., optionally substituted C 3-6 carbocyclyl) .
  • R 2 when –CR 1 R 1’ R 2 is isopropyl or –CH (CH 3 ) (CH 2 -OH) , then R 4 is not hydrogen, –COOH, or –CN.
  • R 2 can be an optionally substituted alkyl, an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl, which is further defined herein.
  • the compound of Formula I can be characterized as having a Formula I-1:
  • R 2 , R 100 , n, and R 4 are defined herein.
  • the compound of Formula I can be characterized as having a Formula I-2:
  • R 1 , R 1’ , R 2 , R 4 , R 100 , and n are defined herein.
  • the compound of Formula I can be characterized as having a Formula I-3:
  • R 2 , R 100 , n, and R 4 are defined herein.
  • R 2 is not methyl, for example, when R 2 is cyclohexyl or phenyl
  • the compound of Formula I-3 has at least one chiral center, which can exist in the form of individual enantiomers, or a mixture of the two enantiomers in any ratio, including racemic mixture, when applicable.
  • the compound of Formula I-3 can exist in the form of individual stereoisomers, or any stereoisomeric mixtures thereof.
  • representative compounds of Formula I-3 having one chiral center can be prepared in racemic forms or can be separated into individual enantiomers, e.g., using chiral HPLC.
  • the individual enantiomer is enriched, for example, the individual enantiomer can be substantially free of the other enantiomer (e.g., less than 20%, less than 15%, less than 10%, less than 5%, less than 2%, less than 1%, or less than 0.5%, or not detected, as determined by analytical chiral HPLC) .
  • R 1 and R 1’ in Formula I are independently hydrogen or an optionally substituted C 1-4 alkyl (e.g., C 1-4 alkyl) .
  • both R 1 and R 1’ are hydrogen.
  • one of R 1 and R 1’ is hydrogen and the other of R 1 and R 1’ is a C 1-4 alkyl (such as a methyl, ethyl, etc. ) .
  • one of R 1 and R 1’ is hydrogen and the other of R 1 and R 1’ is a C 1-4 alkyl (such as a methyl, ethyl, etc.
  • both of R 1 and R 1’ are C 1-4 alkyl (such as a methyl, ethyl, etc. ) . In some embodiments, both of R 1 and R 1’ are C 1-4 alkyl (such as a methyl, ethyl, etc. ) , optionally substituted with one or more substituents, e.g., one substituent such as hydroxyl.
  • one of R 1 and R 1’ in Formula I can also be OH and the other of R 1 and R 1’ is defined herein.
  • one of R 1 and R 1’ in Formula I can also be a halogen (e.g., F) and the other of R 1 and R 1’ is defined herein.
  • both of R 1 and R 1’ in Formula I can be a halogen (e.g., F) .
  • a in Formula I is O, CH 2 , S, SO or SO 2 .
  • A is O.
  • A is CH 2 .
  • A can also be S. It should be noted that in any of the embodiments described herein, as applicable, corresponding embodiments with A as CO, CF 2 , NH, N (C 1-4 alkyl) , or a protected NH, are also contemplated and are novel compounds of the present invention.
  • R 3 is hydrogen. In some embodiments, R 3 is an optionally substituted alkyl that can be metabolically converted into a corresponding compound with R 3 being hydrogen. In some embodiments, R 3 can be an optionally substituted C 1-4 alkyl. For example, in some embodiments, R 3 can be a C 1-4 alkyl, such as a methyl, optionally substituted with one or more groups (such as one) independently selected from –OH, a protected hydroxyl group, and –OR, wherein R can be any feasible group that can be stably attached to oxygen such as an oxygen atom substituent described herein.
  • –OR can be an O-linked amino acid, -OP (O) (OH) 2 , or –OC (O) -R 101 , wherein R 101 can be an optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted -C 1-6 alkylene-COOH, optionally substituted C 3-6 cycloalkyl, optionally substituted 4-7 membered heterocyclyl, optionally substituted 5-10 membered heteroaryl, or optionally substituted aryl.
  • R 3 can be a C 1-4 alkyl, such as a methyl, optionally substituted with one or more, such as one, –OH or a protected hydroxyl group.
  • Suitable hydroxyl protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • the term "O-linked amino acid” means any amino acid, naturally occurring or synthetic, linked to a molecule via an oxygen of a carboxyl group of said amino acid, preferably via the carboxyl group of the carboxy terminus of said amino acid.
  • Preferred examples of amino acids are (S) -2-amino-3-methyl-butyric acid, (2S, 3S) -2-amino-3-methyl-pentanoic acid and (S) -2-amino-propionic acid.
  • R 2 can be an optionally substituted carbocyclyl.
  • R 2 can be an optionally substituted C 3-6 cycloalkyl, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 2 can be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which can be optionally substituted with 1 or 2 substituents independently selected from F, methyl and hydroxyl.
  • R 2 can be an alkyl such as a C 1-4 alkyl optionally substituted with one or more substituents independently selected from optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , optionally substituted 5-10 membered heteroaryl, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • substituents independently selected from optionally substituted C 3-6 cycloalkyl, optionally substituted phenyl, optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , optionally substituted 5-10 membered heteroaryl, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one substituent selected from optionally substituted C 3-6 cycloalkyl (e.g., as described herein) , optionally substituted phenyl, optionally substituted 4-7 membered heterocyclyl (e.g., as described herein) , and optionally substituted 5-10 membered heteroaryl (e.g., as described herein) .
  • C 1-4 alkyl e.g., methyl substituted with one substituent selected from optionally substituted C 3-6 cycloalkyl (e.g., as described herein) , optionally substituted phenyl, optionally substituted 4-7 membered heterocyclyl (e.g., as described herein) , and optionally substituted 5-10 membered heteroaryl (e.g., as described herein) .
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one optionally substituted C 3-6 cycloalkyl, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • C 1-4 alkyl e.g., methyl substituted with one optionally substituted C 3-6 cycloalkyl, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which can be optionally substituted with 1 or 2 substituents independently selected from F, methyl and hydroxyl.
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one phenyl group which is optionally substituted with 1-5 (e.g., 1, 2, or 3) substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc.
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one phenyl group which is optionally substituted with 1-5 (e.g., 1, 2, or 3) substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc.
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one 5-or 6-membered heteroaryl group (e.g., as described herein, such as pyridinyl, pyrrazolyl, isoxazolyl, etc.
  • substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. ) optionally substituted with 1-3 fluorine, C 1-4 alkyl substituted with one or two hydroxyl groups, C 1-4 alkoxy (e.g., methoxy, ethoxy, etc. ) optionally substituted with 1-3 fluorine, hydroxyl, and CN.
  • 1-5 e.g., 1, 2, or 3
  • substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. ) optionally substituted with 1-3 fluorine, C 1-4 alkyl substituted with one or two hydroxyl groups, C 1-4 alkoxy (e.g., methoxy, ethoxy, etc. ) optionally substituted with 1-3 fluorine, hydroxyl, and CN.
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one 5, 6-or 6, 6-bicyclic heteroaryl group (e.g., as described herein, such as indazolyl, etc. ) , which is optionally substituted with 1-5 (e.g., 1, 2, or 3) substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. ) optionally substituted with 1-3 fluorine, C 1-4 alkyl substituted with one or two hydroxyl groups, C 1-4 alkoxy (e.g., methoxy, ethoxy, etc.
  • 1-5 e.g., 1, 2, or 3
  • substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. ) optionally substituted with 1-3 fluorine
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , e.g., with one or two substituents independently selected from a nitrogen protecting group, as applicable, C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 2 can be a C 1-4 alkyl (e.g., methyl) substituted with one optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , e.g., with one or two substituents independently selected from a nitrogen protecting group, as applicable, C 1-4 alkyl optionally substituted with 1-3 fluorine,
  • R 2 can be an optionally substituted heterocyclyl, preferably an optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • an optionally substituted heterocyclyl preferably an optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is
  • R 2 can be an optionally substituted 5 or 6 membered saturated heterocyclyl containing one or two heteroatoms, such as one oxygen, one oxygen and one nitrogen, one nitrogen, two nitrogen atoms, etc.
  • R 2 can be piperidinyl or tetrahydropyranyl, which can be optionally substituted, for example, the piperidinyl can in some embodiments be substituted with one nitrogen atom substituent as described herein such as a nitrogen protecting group, e.g., -C (O) -C 1-4 alkyl or –C (O) -O-C 1-4 alkyl.
  • a nitrogen protecting group e.g., -C (O) -C 1-4 alkyl or –C (O) -O-C 1-4 alkyl.
  • R 2 can be an optionally substituted aryl such as an optionally substituted phenyl, e.g., with one or more such as 1 or 2 substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, -CN, and halogen, wherein Pg 1 is an oxygen protecting group.
  • aryl such as an optionally substituted phenyl, e.g., with one or more such as 1 or 2 substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, -CN, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 2 can be an optionally substituted phenyl, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, C 1-4 alkyl substituted with one or two hydroxyl groups, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, -CN, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 2 can be a phenyl optionally substituted with 1-5 (e.g., 1, 2, or 3) substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. ) optionally substituted with 1-3 fluorine, C 1-4 alkoxy (e.g., methoxy, ethoxy, etc. ) optionally substituted with 1-3 fluorine, hydroxyl, and CN.
  • 1-5 e.g., 1, 2, or 3
  • substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. ) optionally substituted with 1-3 fluorine, C 1-4 alkoxy (e.g., methoxy, ethoxy, etc. ) optionally substituted with 1-3 fluorine, hydroxyl, and CN.
  • Heteroaryl groups are also suitable as R 2 groups for Formula I (e.g., Formula I-1, I-2, I-3, or I-4) .
  • R 2 can be an optionally substituted 5-10 membered heteroaryl, e.g., 5-10 membered heteroaryl containing 1-3 heteroatoms independently selected from O, N, and S, wherein the heteroaryl is optionally substituted, e.g., with 1-5, such as with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, C 1-4 alkyl substituted with one or two hydroxyl groups, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, -CN, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 2 can be an optionally substituted 5 or 6 membered heteroaryl, such as pyridyl, thiophenyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, isothiazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, and pyrazinyl, optionally substituted, e.g., with 1-5, such as with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, C 1-4 alkyl substituted with one or two hydroxyl groups, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, -CN, and halogen, wherein Pg 1 is an oxygen protecting group.
  • heteroaryl such as pyr
  • R 2 can be a 5, 6–bicyclic or 6, 6-bicyclic heteroaryl, such as indolyl, pyrrolopyridinyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, purinyl, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl, optionally substituted, e.g.,
  • R 2 can be a pyridyl (e.g., 2-, 3-, or 4- pyridyl) , indazolyl, isoxazolyl, or pyrazolyl, which can be optionally substituted as described herein.
  • pyridyl e.g., 2-, 3-, or 4- pyridyl
  • R 2 can be selected from the following:
  • R 2 can be selected from the following:
  • the phenyl ring in Formula I (e.g., Formula I-1, I-2, I-3, or I-4) is typically substituted with 2 or 3 independently selected R 100 groups, i.e., n is 2 or 3.
  • R 100 at each occurrence is independently F, Cl, Br, CF 3 , or methyl.
  • one instance of R 100 is CF 3 .
  • Various substitution patterns for the phenyl ring in Formula I (e.g., Formula I-1, I-2, I-3, or I-4) are suitable.
  • two of the R 100 groups are attached to the ortho-positions of the linker A in Formula I, for example, as follows:
  • the R 100 together with the phenyl ring they are attached to form In some embodiments, the R 100 together with the phenyl ring they are attached to form
  • R 4 at the azauracil ring in Formula I can vary.
  • R 4 can be C 1-6 alkyl or C 3-6 cycloalkyl, each optionally substituted with 1-3 fluorine.
  • R 4 can be hydrogen, -CN, -COOH, methyl, ethyl, cyclopropyl, isopropyl, or propyl.
  • R 4 in Formula I-1 can be hydrogen, –CN or methyl.
  • R 4 in Formula I-1 can be methyl, ethyl, cyclopropyl, isopropyl, or propyl.
  • R 4 in Formula I-2 can be hydrogen, –CN or methyl. In some preferred embodiments, R 4 in Formula I-2 can be methyl, ethyl, cyclopropyl, isopropyl, or propyl. In some preferred embodiments, R 4 in Formula I-3 can be hydrogen, –CN or methyl. In some preferred embodiments, R 4 in Formula I-3 can be methyl, ethyl, cyclopropyl, isopropyl, or propyl. In some preferred embodiments, R 4 in Formula I-4 can be hydrogen, –CN or methyl. In some preferred embodiments, R 4 in Formula I-4 can be methyl, ethyl, cyclopropyl, isopropyl, or propyl.
  • the present invention provides a compound of Formula II, or a pharmaceutically acceptable salt thereof:
  • R 5 is an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl; or R 5 is -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , wherein each of the C 1-6 alkyl is independently selected and optionally substituted;
  • A is O, CH 2 , S, SO or SO 2 ,
  • R 3 is hydrogen or an optionally substituted alkyl
  • R 100 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • R 4 is hydrogen, -CN, -COOH, optionally substituted alkyl (e.g., optionally substituted C 1- 6 alkyl) , or optionally substituted carbocyclyl (e.g., optionally substituted C 3-6 carbocyclyl) .
  • R 5 can be an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, which is further defined herein.
  • the compound of Formula II can be characterized as having a Formula II-1:
  • R 5 , R 100 , n, and R 4 are defined herein.
  • R 5 can be an optionally substituted C 3-6 cycloalkyl, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 5 can be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which can be optionally substituted with 1 or 2 substituents independently selected from F, methyl and hydroxyl.
  • R 5 can be an optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, -C (O) -C 1-4 alkyl, -C (O) -O-C 1-4 alkyl, and halogen, wherein Pg 1 is an oxygen protecting group.
  • heterocyclyl e.g., piperidinyl or tetrahydropyranyl
  • R 5 can be an optionally substituted 5 or 6 membered saturated heterocyclyl containing one or two heteroatoms, such as one oxygen, one oxygen and one nitrogen, one nitrogen, two nitrogen atoms, etc.
  • R 5 can be piperidinyl or tetrahydropyranyl, which can be optionally substituted, for example, the piperidinyl can in some embodiments be substituted with one nitrogen atom substituent as described herein such as a nitrogen protecting group (e.g., benzyl or substituted benzyl, -C (O) -C 1-4 alkyl or -C (O) -O-C 1-4 alkyl, such as acetyl) .
  • a nitrogen protecting group e.g., benzyl or substituted benzyl, -C (O) -C 1-4 alkyl or -C (O) -O-C 1-4 alkyl, such as acetyl
  • R 5 is an optionally substituted phenyl, e.g., with one or more such as 1 or 2 substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, -CN, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 5 can be a phenyl optionally substituted with 1-5 (e.g., 1, 2, or 3) substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. ) optionally substituted with 1-3 fluorine, C 1-4 alkoxy (e.g., methoxy, ethoxy, etc. ) optionally substituted with 1-3 fluorine, hydroxyl, and CN.
  • 1-5 e.g., 1, 2, or 3
  • substituents independently selected from F
  • R 5 can be an optionally substituted 5-10 membered heteroaryl (e.g., as described herein) .
  • R 5 can be a 5-10 membered heteroaryl containing 1-3 heteroatoms independently selected from O, N, and S, wherein the heteroaryl is optionally substituted, e.g., with 1-5, such as with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, C 1-4 alkyl substituted with one or two hydroxyl groups, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, -CN, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 5 can be an optionally substituted 5 or 6-membered heteroaryl, e.g., as described herein, such as pyridinyl, pyrrazolyl, or isoxazolyl, etc.
  • R 5 can be an optionally substituted 5, 6-or 6, 6-bicyclic heteroaryl, e.g., as described herein, such as indazolyl, etc.
  • R 5 can be selected from the following:
  • A, R 3 , R 100 , n and R 4 suitable for Formula II include any of those described herein in the context of Formula I.
  • a in Formula II is O or CH 2 , more preferably, O.
  • a in Formula II is S.
  • R 3 in Formula II can be hydrogen or an optionally substituted alkyl that can be metabolically converted into a corresponding compound with R 3 being hydrogen.
  • R 3 can be a C 1-4 alkyl, such as a methyl, optionally substituted with one or more groups (such as one) independently selected from –OH, O-linked amino acid, -OP (O) (OH) 2 , and –OC (O) -R 101 , wherein R 101 can be an optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted -C 1-6 alkylene-COOH, optionally substituted C 3-6 cycloalkyl, optionally substituted 4-7 membered heterocyclyl, optionally substituted 5-10 membered heteroaryl, or optionally substituted aryl.
  • R 101 can be an optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted -C 1-6 alkylene-COOH, optionally substituted C 3-6 cycloalkyl, optionally substituted 4-7 membered heterocyclyl, optionally substituted 5-10 membered heteroaryl, or
  • the phenyl ring in Formula II is also typically substituted with 2 or 3 independently selected R 100 groups, i.e., n is 2 or 3.
  • R 100 at each occurrence is independently F, Cl, Br, CF 3 , or methyl.
  • one instance of R 100 is CF 3 .
  • the R 100 together with the phenyl ring they are attached to form In some embodiments, the R 100 together with the phenyl ring they are attached to form
  • the substituent R 4 at the azauracil ring in Formula II can be C 1-6 alkyl or C 3-6 cycloalkyl, each optionally substituted with 1-3 fluorine.
  • R 4 can be hydrogen, -CN, -COOH, methyl, ethyl, cyclopropyl, isopropyl, or propyl.
  • R 4 in Formula II e.g., Formula II-1) can be hydrogen, –CN or methyl.
  • R 4 in Formula II (e.g., Formula II-1) can be methyl, ethyl, cyclopropyl, isopropyl, or propyl.
  • R 3 , R 100 , n and R 4 include any of those described herein.
  • the present invention are also directed to TR beta agonists without a pyridazinone structural unit.
  • the inventors have unexpectedly found that various heterocyclic structures can be used to replace the pyridazinone structural unit and achieve similar or better potency.
  • the present invention provides a compound of Formula III, or a pharmaceutically acceptable salt thereof:
  • Het is a bicyclic heteroaryl, e.g., 5, 6-bicyclic or 6, 6-bicyclic heteroaryl, which is substituted with 1-2 substituents independently selected from a nitrogen protecting group, -OH, -OPg 1 , an optionally substituted alkyl, -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, wherein each of the C 1-6 alkyl is independently selected and optionally substituted; wherein Pg 1 is an oxygen protecting group, wherein the bicyclic heteroaryl, e.g., 5, 6-bicyclic or 6, 6-bicyclic heteroaryl is optionally further substituted as valence permits;
  • A is null, O, CH 2 , S, SO or SO 2 ,
  • R 100 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • R 4 is hydrogen, -CN, -COOH, optionally substituted C 1-6 alkyl, or optionally substituted C 3-6 carbocyclyl.
  • any of the 5, 6-bicyclic or 6, 6-bicyclic heteroaryl described herein can be used as Het in Formula III.
  • the 5, 6-bicyclic or 6, 6-bicyclic heteroaryl can be selected from indolyl, pyrrolopyridine, and indazolyl.
  • a in Formula III is typically S, O, or CH 2 .
  • A is O.
  • A is S.
  • A is CH 2 .
  • A is understood as null.
  • the Het in Formula III is indolyl.
  • the present invention provides a compound of Formula III-1, or a pharmaceutically acceptable salt thereof:
  • R 6 is hydrogen or a nitrogen protecting group
  • R 7 is an optionally substituted alkyl, -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, wherein each of the C 1-6 alkyl is independently selected and optionally substituted;
  • A is O, CH 2 , S, SO or SO 2 ,
  • each of R 100 and R 102 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • p 0, 1, 2, 3, or 4
  • R 4 is hydrogen, -CN, -COOH, optionally substituted C 1-6 alkyl, or optionally substituted C 3-6 carbocyclyl.
  • the compound of Formula III-1 can be characterized as having a Formula III-1A:
  • R 7 , R 100 , n, and R 4 are defined herein.
  • the Het in Formula III is a pyrrolopyridine.
  • the present invention provides a compound of Formula III-2, or a pharmaceutically acceptable salt thereof:
  • R 6 is hydrogen or a nitrogen protecting group
  • R 7 is an optionally substituted alkyl, -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, wherein each of the C 1-6 alkyl is independently selected and optionally substituted;
  • A is O, CH 2 , S, SO or SO 2 ,
  • each of R 100 and R 102 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • p 0, 1, 2, or 3
  • R 4 is hydrogen, -CN, -COOH, optionally substituted C 1-6 alkyl, or optionally substituted C 3-6 carbocyclyl.
  • the compound of Formula III-2 can be characterized as having a Formula III-2A:
  • R 7 , R 100 , n, and R 4 are defined herein.
  • the Het in Formula III is indazolyl.
  • the present invention provides a compound of Formula III-3, or a pharmaceutically acceptable salt thereof:
  • R 6 is hydrogen or a nitrogen protecting group
  • R 7 is an optionally substituted alkyl, -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, wherein each of the C 1-6 alkyl is independently selected and optionally substituted;
  • A is O, CH 2 , S, SO or SO 2 ,
  • each of R 100 and R 102 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • p 0, 1, 2, or 3
  • R 4 is hydrogen, -CN, -COOH, optionally substituted C 1-6 alkyl, or optionally substituted C 3-6 carbocyclyl.
  • the compound of Formula III-3 can be characterized as having a Formula III-3A:
  • R 7 , R 100 , n, and R 4 are defined herein.
  • the Het in Formula III is indazolyl which is connected to the phenyl group directly, i.e., A is null.
  • the present invention provides a compound of Formula III-4, or a pharmaceutically acceptable salt thereof:
  • R 7 is an optionally substituted alkyl, -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, wherein each of the C 1-6 alkyl is independently selected and optionally substituted;
  • R 102 at each occurrence is independently -OH, -OPg 1 , F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy, wherein Pg 1 is an oxygen protecting group,
  • R 100 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • p 0, 1, 2, 3, or 4
  • R 4 is hydrogen, -CN, -COOH, optionally substituted C 1-6 alkyl, or optionally substituted C 3-6 carbocyclyl.
  • the compound of Formula III-4 can be characterized as having a Formula III-4A:
  • R 102 is OH or O-Pg 1 , and R 7 , R 100 , n, and R 4 are defined herein.
  • a in Formula III-1 to III-3 is typically S, O or CH 2 .
  • A is S.
  • A is O.
  • A is CH 2 .
  • the indole ring in Formula III-1 is not further substituted, i.e., p is 0. However, in some embodiments, the indole ring can also be further substituted with up to 4 substituents.
  • the (R 102 ) p in Formula III-1 should be understood as encompassing substitution at any of the available positions in the indole ring, including the 2-position, not just the benzene portion of the indole ring.
  • each substituent of R 102 can be independently selected, for example, from F, Cl, methyl, CF 3 , cyclopropyl, cyclobutyl, methoxy, cyclopropoxy, and cyclobutoxy.
  • the pyrrolopyridine ring in Formula III-2 is not further substituted, i.e., p is 0.
  • the pyrrolopyridine ring can also be further substituted with up to 3 substituents.
  • the (R 102 ) p in Formula III-2 should be understood as encompassing substitution at any of the available positions in the pyrrolopyridine ring, not limiting to the pyridine ring.
  • each substituent of R 102 can be independently selected, for example, from F, Cl, methyl, CF 3 , cyclopropyl, cyclobutyl, methoxy, cyclopropoxy, and cyclobutoxy.
  • the indazole ring in Formula III-3 is not further substituted, i.e., p is 0.
  • the indazole ring can also be further substituted with up to 3 substituents.
  • each substituent of R 102 can be independently selected, for example, from F, Cl, methyl, CF 3 , cyclopropyl, cyclobutyl, methoxy, cyclopropoxy, and cyclobutoxy.
  • the indazole ring in Formula III-4 is typically further substituted, for example, with p being 1.
  • at least one instance of R 102 in Formula III-4 is hydroxyl or a protected hydroxyl group (i.e., O-Pg 1 ) .
  • the indazole ring can be further substituted with up to 3 substituents, which can be independently selected, for example, from F, Cl, methyl, CF 3 , cyclopropyl, cyclobutyl, methoxy, cyclopropoxy, and cyclobutoxy.
  • R 6 in Formula III-1 to III-3 is typically hydrogen.
  • R 6 can be a nitrogen protecting group that can be deprotected either in vitro or in vivo (metabolically cleaved) to provide a corresponding compound with R 6 being hydrogen.
  • R 6 can be a –C (O) -C 1-4 alkyl or –C (O) -O-C 1-4 alkyl.
  • Suitable nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • R 7 can be isopropyl or an optionally substituted C 3-6 cycloalkyl, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 7 is -CONH 2 , -CONH (C 1-4 alkyl) , or -CON (C 1-4 alkyl) (C 1-4 alkyl) , wherein each of the C 1-4 alkyl is independently selected and optionally substituted, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 7 can be an optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • heterocyclyl e.g., piperidinyl or tetrahydropyranyl
  • R 7 in Formula III-1 to III-4 can be a moiety –CR 1 R 1’ R 2 as defined for Formula I or R 5 as defined for Formula II, including applicable subformula, see e.g., hereinabove.
  • Non-limiting exemplary useful groups for R 7 in Formula III-1 to III-4 include (1) C 1-6 alkyls such as isopropyl; (2) C 3-6 cycloalkyls such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which can be optionally substituted with 1 or 2 substituents independently selected from F, methyl and hydroxyl; (3) phenyl, or 5 or 6 membered heteroaryl (e.g., as described herein, such as pyridyl, pyrrazolyl, isoxazolyl, etc.
  • C 1-6 alkyls such as isopropyl
  • C 3-6 cycloalkyls such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which can be optionally substituted with 1 or 2 substituents independently selected from F, methyl and hydroxyl
  • C 1-4 alkyl e.g., methyl
  • one C 3-6 cycloalkyl group 4-7 membered heterocyclic group, 5 or 6 membered heteroaryl group (e.g., as described herein, such as pyridyl, pyrrazolyl, isoxazolyl, etc.
  • each of the cycloalkyl, heterocyclic, heteroaryl, or phenyl is optionally substituted with 1-5 (e.g., 1, 2, or 3) substituents independently selected from F, Cl, Br, C 1-4 alkyl (e.g., methyl, ethyl, propyl, isopropyl, etc. ) optionally substituted with 1-3 fluorine, C 1-4 alkoxy (e.g., methoxy, ethoxy, etc.
  • ⁇ optionally substituted with 1-3 fluorine, hydroxyl, and CN; and (5) 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , which can be optionally substituted, for example, the piperidinyl can be in some embodiments be substituted with one nitrogen atom substituent as described herein such as a nitrogen protecting group.
  • 4-7 membered heterocyclyl e.g., piperidinyl or tetrahydropyranyl
  • the piperidinyl can be in some embodiments be substituted with one nitrogen atom substituent as described herein such as a nitrogen protecting group.
  • R 100 , n and R 4 suitable for Formula III include any of those described herein in the context of Formula I or II.
  • the phenyl ring (not the indole ring) in Formula III is also typically substituted with 2 or 3 independently selected R 100 groups, i.e., n is 2 or 3.
  • R 100 at each occurrence is independently F, Cl, Br, CF 3 , or methyl.
  • one instance of R 100 is CF 3 .
  • the R 100 together with the phenyl ring they are attached to form In some embodiments, the R 100 together with the phenyl ring they are attached to form
  • the substituent R 4 at the azauracil ring in Formula III can be C 1-6 alkyl or C 3-6 cycloalkyl, each optionally substituted with 1-3 fluorine.
  • R 4 can be hydrogen, -CN, -COOH, methyl, ethyl, cyclopropyl, isopropyl, or propyl.
  • R 4 in Formula III e.g., Formula III-1 to III-4
  • R 4 in Formula III can be hydrogen, –CN or methyl.
  • R 4 in Formula III (e.g., Formula III-1 to III-4) can be methyl, ethyl, cyclopropyl, isopropyl, or propyl.
  • R 100 , n and R 4 include any of those described herein.
  • the present invention also provides a compound that does not contain an azauracil unit, but instead has a phosphoric acid or ester thereof.
  • the present invention provides a compound of Formula I-X or II-X, or a pharmaceutically acceptable salt or ester thereof:
  • R 2 is an optionally substituted alkyl, an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl, or R 2 is -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , wherein each of the C 1-6 alkyl is independently selected and optionally substituted,
  • A is O, CH 2 , S, SO or SO 2 ,
  • R 3 is hydrogen or an optionally substituted alkyl
  • R 5 is an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, or R 5 is -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , wherein each of the C 1-6 alkyl is independently selected and optionally substituted,
  • R 100 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • L is J 1 -J 2 -J 3 , wherein each of J 1 , J 2 , and J 3 is independently null, O, NH, or an optionally substituted C 1-6 alkylene, provided that at least one of J 1 , J 2 , and J 3 is an optionally substituted C 1-6 alkylene, and L does not contain an O-O or O-N bond.
  • L is C 1-4 alkylene or –O-C 1-4 alkylene, for example, L is ethylene or –O-CH 2 -, wherein the CH 2 is linked to the phosphine atom.
  • an ester, including monoester or diester, of the compound having Formula I-X or II-X is provided, such as a pharmaceutically acceptable ester.
  • the present invention provides an ethyl ester (such as diethyl ester) of the compound having Formula I-X or II-X.
  • the ester can be a cyclic ester, which can be derived from a diol such as a 1, 2-diol or 1, 3-diol.
  • R 1 , R 1’ , R 2 , R 3 , R 5 , A, R 100 , and n suitable for Formula I-X or II-X include any of those described and/or preferred herein in the context of Formula I or II, as applicable.
  • the present invention provides a compound of Formula III-X, or a pharmaceutically acceptable salt or ester thereof:
  • Het is a bicyclic heteroaryl, e.g., 5, 6-bicyclic or 6, 6-bicyclic heteroaryl, which is substituted with 1-2 substituents independently selected from a nitrogen protecting group, -OH, -OPg 1 , an optionally substituted alkyl, -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, wherein each of the C 1-6 alkyl is independently selected and optionally substituted; wherein Pg 1 is an oxygen protecting group, wherein the bicyclic heteroaryl, e.g., 5, 6-bicyclic or 6, 6-bicyclic heteroaryl is optionally further substituted as valence permits;
  • A is null, O, CH 2 , S, SO or SO 2 ,
  • R 100 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • L is J 1 -J 2 -J 3 , wherein each of J 1 , J 2 , and J 3 is independently null, O, NH, or an optionally substituted C 1-6 alkylene, provided that at least one of J 1 , J 2 , and J 3 is an optionally substituted C 1-6 alkylene, and L does not contain an O-O or O-N bond.
  • L is C 1-4 alkylene or –O-C 1-4 alkylene, for example, L is ethylene or –O-CH 2 -, wherein the CH 2 is linked to the phosphine atom.
  • an ester, including monoester or diester, of the compound having Formula III-X is provided, such as a pharmaceutically acceptable ester.
  • the present invention provides an ethyl ester (such as diethyl ester) of the compound having Formula III-X.
  • the ester can be a cyclic ester, which can be derived from a diol such as a 1, 2-diol or 1, 3-diol.
  • Het, A, R 100 , and n suitable for Formula III-X include any of those described and/or preferred herein in the context of Formula III-1, III-2, III-3, or III-4, as applicable.
  • the present invention provides a compound selected from Compound Nos. 1-99, or a pharmaceutically acceptable salt thereof:
  • such CH 2 liner can be prepared from a cyanomethylene starting material, which can be deprotonated to generate a carbanion to react with a chloropyridazine derivative, which can then be hydrolyzed and decarboxylated to generate a CH 2 linker.
  • a chloropyridazine derivative which can then be hydrolyzed and decarboxylated to generate a CH 2 linker.
  • Compounds with SO or SO 2 as linker A can be prepared from oxidation of the corresponding analog with S as the linker A.
  • a typical synthesis of a compound of Formula I-2 can start with reacting an aminophenol S-1 with a pyridazine S-2 to form an aryl ether S-3.
  • the leaving group Lg 1 in S-2 is typically Cl, although other leaving groups such as F can also be used and sometimes maybe advantageous.
  • Hydrolysis of the chloropyridazine S-3 can then yield the pyridazinone compound S-4.
  • the aniline function in S-4 can then be converted into an azauracil ring following known procedure or those described herein to provide the compound of Formula I-2.
  • the variables R 1 , R 1’ , R 2 , R 4 , R 100 , and n in Scheme 1 are defined herein.
  • R 4 is –CN
  • the conversion of S-4 into cyanoazauracil can be achieved through diazotization of S-4, followed by reacting with a cyanoacetamide derivative S-5 to form an intermediate IM-1, which can then be cyclized to provide a compound of Formula I-2, Formula I-2-A.
  • Scheme 2 The variables R 1 , R 1’ , R 2 , R 100 , and n in Scheme 2 are defined herein.
  • R 4 is an optionally substituted alkyl or cycloalkyl, such as methyl, ethyl, isopropyl, cyclopropyl, etc.
  • the conversion of S-4 into an azauracil ring can be achieved through first converting the aniline into a hydrazine S-6, which is then reacted with an acid S-7 to form an intermediate IM-2, this intermediate can then be converted into intermediate IM-3 through reacting with carbamate S-8.
  • the intermediate IM-3 can then by cyclized into an azauracil following similar conditions as described for Scheme 2.
  • Conditions for the transformations in Scheme 3 are known in the art and also exemplified herein.
  • the variables R 1 , R 1’ , R 2 , R 100 , and n in Scheme 3 are defined herein.
  • S-2 can be prepared by following known procedures.
  • S-2 can be prepared by reacting dichloropyridazine with a carboxylic acid under a decarboxylative coupling condition in the presence of an oxidant.
  • Example 6 shows a typical procedure for such a coupling reaction.
  • S-2 can be prepared by first coupling 4-bromo-1, 2, 3, 6-tetrahydropyridazine-3, 6-dione with an appropriate reagent such as an organoboron reagent or other suitable reagent to form a pyridazine-dione derivative, which can be converted into S-2 following known procedures.
  • An example of this method is shown in Example 19.
  • Example 24 shows another method for preparing S-2, where an appropriate precursor (in Example 24, a benzyl substituted dichloropyridazine) can be deprotonated and then reacted with R 1 -Lg (in Example 24, Me-I) .
  • an appropriate precursor in Example 24, a benzyl substituted dichloropyridazine
  • R 1 -Lg in Example 24, Me-I
  • Other compounds can be prepared similarly.
  • compound S-4 can be prepared by first reacting compound S-1 with dichloropyridazine as shown in Scheme 4.
  • compound S-1 is first converted into compound S-9, which is then followed by hydrolysis of the chloropyridazine and protecting the aniline NH 2 to form the compound S-10.
  • This is followed by introducing appropriate C (R 1 ) (R 1’ ) (R 2 ) group, for example, by reacting compound S-10 with an appropriate Grignard reagent followed by oxidation.
  • compound S-4 can be obtained.
  • An example of this method is shown in Example 7.
  • the variables R 1 , R 1’ , R 2 , R 100 , and n in Scheme 4 are defined herein.
  • Pg 2 can be any suitable amine protecting group, such as benzoyl.
  • the present disclosure also provides a method of preparing compounds of Formula I-1 as shown in Scheme 1A.
  • the pyridazinone IM-4 can be reduced to provide IM-5, which can react with an appropriate aldehyde (or other suitable reactants) under suitable condition to provide IM-6, which upon oxidation can provide a compound of Formula I-1.
  • Example 25 provides a representative procedure.
  • an appropriate S-10 can be reduced, which is then reacted with an appropriate aldehyde to form a compound of S-4, where R 1 and R 1’ are both hydrogen, which can also be converted into a compound of Formula I-1.
  • a representative procedure is shown in Example 26.
  • Indole derivatives of Formula III-1A can be synthesized following the general strategy herein. An example of synthesis is also described in detail in the Examples section. Briefly, as shown in Scheme 5 below, a 5-hydroxyindole derivative S-13 can react with a para-F nitrophenyl compound S-14 (or a similar nitrobenzene derivative with a leaving group at the para-position to the nitro group) , to obtain an aryl ether S-15. The nitro group can then be reduced to an NH 2 group, which can be converted into an azauracil ring follow the general strategies described herein to obtain a compound of Formula III-1A.
  • the indole S-13 can be readily synthesized by various indole synthesis such as Fisher indole synthesis. Reduction of nitro to NH 2 is also well known.
  • the variables R 4 , R 6 , R 7 , R 100 , R 102 , n and p in Scheme 5 are defined herein.
  • Compounds of Formula III-2A, and III-3A can be prepared similarly, except a corresponding pyrrolopyridine or indazole starting material is used.
  • protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
  • Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in “Protective Groups in Organic Synthesis” , 4 th ed. P.G.M. Wuts; T.W. Greene, John Wiley, 2007, and references cited therein.
  • the reagents for the reactions described herein are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the reagents are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA) , Sigma (St.
  • Certain embodiments are directed to a pharmaceutical composition comprising one or more of the compounds of the present disclosure.
  • the pharmaceutical composition can optionally contain a pharmaceutically acceptable excipient.
  • the pharmaceutical composition comprises a compound of the present disclosure (e.g., a compound of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , a compound of Formula II (e.g., Formula II-1) , a compound of Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , a compound of Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable excipient.
  • Pharmaceutically acceptable excipients are known in the art.
  • Non-limiting suitable excipients include, for example, encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, carriers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof. See also Remington's The Science and Practice of Pharmacy, 21st Edition, A.R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, Md., 2005; incorporated herein by reference) , which discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof.
  • absorption accelerators such as absorption accelerators, antioxidants, binders, buffers, carriers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders
  • the pharmaceutical composition can include any one or more of the compounds of the present disclosure.
  • the pharmaceutical composition comprises a compound of any of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , a compound of Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, or a pharmaceutically acceptable salt thereof, e.g., in a therapeutically effective amount.
  • the pharmaceutical composition can comprise a therapeutically effective amount of a compound selected from compounds 1-99, or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition can also be formulated for delivery via any of the known routes of delivery, which include but are not limited to oral, parenteral, inhalation, etc.
  • the pharmaceutical composition can be formulated for oral administration.
  • the oral formulations can be presented in discrete units, such as capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
  • Excipients for the preparation of compositions for oral administration are known in the art.
  • Non-limiting suitable excipients include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1, 3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl cellulose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl
  • the pharmaceutical composition is formulated for parenteral administration (such as intravenous injection or infusion, subcutaneous or intramuscular injection) .
  • the parenteral formulations can be, for example, an aqueous solution, a suspension, or an emulsion.
  • Excipients for the preparation of parenteral formulations are known in the art. Non-limiting suitable excipients include, for example, 1, 3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water and mixtures thereof.
  • the pharmaceutical composition is formulated for inhalation.
  • the inhalable formulations can be, for example, formulated as a nasal spray, dry powder, or an aerosol administrable through a metered-dose inhaler.
  • Excipients for preparing formulations for inhalation are known in the art. Non-limiting suitable excipients include, for example, lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, and mixtures of these substances.
  • Sprays can additionally contain propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
  • the pharmaceutical composition can include various amounts of the compounds of the present disclosure, depending on various factors such as the intended use and potency and selectivity of the compounds.
  • the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present disclosure.
  • the pharmaceutical composition comprises a therapeutically effective amount of the compound of the present disclosure and a pharmaceutically acceptable excipient.
  • a therapeutically effective amount of a compound of the present disclosure is an amount effective to treat a disease or disorder as described herein, which can depend on the recipient of the treatment, the disease or disorder being treated and the severity thereof, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the compound potency, its rate of clearance and whether or not another drug is co-administered.
  • Compounds of the present disclosure are useful as therapeutic active substances for the treatment and/or prophylaxis of diseases or disorders that are modulated by thyroid hormone receptor agonists.
  • the present disclosure provides a method of treating a disease or disorder in a subject in need thereof.
  • the method comprises administering a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of any of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , a compound of Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, or a pharmaceutically acceptable salt thereof) or a therapeutically effective amount of a pharmaceutical composition described herein.
  • a compound of the present disclosure e.g., a compound of any of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula
  • the administering herein is not limited to any particular route of administration.
  • the administering can be orally, nasally, transdermally, pulmonary, inhalationally, buccally, sublingually, intraperintoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally and parenterally.
  • the administering is orally.
  • Non-limiting examples include obesity, hyperlipidemia, hypercholesterolemia, diabetes (e.g., type 2 diabetes) , non-alcoholic steatohepatitis (NASH) , fatty liver, non-alcoholic fatty liver disease (NAFLD) , bone disease, thyroid axis alteration, atherosclerosis, a cardiovascular disorder, tachycardia, hyperkinetic behavior, hypothyroidism, goiter, attention deficit hyperactivity disorder, learning disabilities, mental retardation, hearing loss, delayed bone age, neurologic or psychiatric disease, thyroid cancer, and combinations thereof.
  • the disease or disorder can be a metabolic disease such as type 2 diabetes or hyperlipidemia.
  • the cardiovascular disease is a coronary artery disease.
  • the method is for treating obesity, hyperlipidemia, hypercholesterolemia, diabetes (e.g., type 2 diabetes) , non-alcoholic fatty liver disease (NAFLD) , non-alcoholic steatohepatitis (NASH) , liver steatosis, atherosclerosis, cardiovascular diseases, hypothyroidism or thyroid cancer, which method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of any of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , a compound of Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition described herein.
  • a compound of the present disclosure e.
  • the present disclosure provides a method of treating a liver disease or disorder such as a non-alcoholic fatty liver disease (NAFLD) in a subject in need thereof.
  • the method comprises administering to the subject a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of any of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , a compound of Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition described herein.
  • a compound of the present disclosure e.g., a compound of any of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) ,
  • the liver disease or disorder is liver fibrosis, hepatocellular carcinoma, or liver steatosis. In some preferred embodiments, the liver disease or disorder is non-alcoholic fatty liver disease (NAFLD) , or non-alcoholic steatohepatitis (NASH) .
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • the present disclosure provides a method of treating a lipid disease or disorder in a subject in need thereof.
  • the method comprises administering to the subject a therapeutically effective amount of a compound of the present disclosure (e.g., a compound of any of Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , a compound of Formula I-X, Formula II-X, or Formula III-X, any one of compounds 1-99, or a pharmaceutically acceptable salt thereof) or a pharmaceutical composition described herein.
  • the lipid disease or disorder is hyperlipidemia and/or hypercholesterolemia.
  • Dosing regimen including doses can vary and be adjusted, which can depend on the recipient of the treatment, the disease or disorder being treated and the severity thereof, the composition containing the compound, the time of administration, the route of administration, the duration of treatment, the compound potency, its rate of clearance and whether or not another drug is co-administered.
  • Het is a 5, 6-bicyclic or 6, 6-bicyclic heteroaryl, which is substituted with 1-2 substituents independently selected from a nitrogen protecting group, -OH, -OPg 1 , an optionally substituted alkyl, -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, wherein each of the C 1-6 alkyl is independently selected and optionally substituted; wherein Pg 1 is an oxygen protecting group, wherein the 5, 6-bicyclic or 6, 6-bicyclic heteroaryl is optionally further substituted as valence permits;
  • A is null, O, CH 2 , S, SO or SO 2 ,
  • each of R 100 at each occurrence is independently F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy,
  • n 1, 2, 3, or 4
  • R 4 is hydrogen, -CN, -COOH, optionally substituted C 1-6 alkyl, or optionally substituted C 3-6 carbocyclyl.
  • R 7 is an optionally substituted alkyl, -COOH or an ester thereof, -CONH 2 , -CONH (C 1-6 alkyl) , -CON (C 1-6 alkyl) (C 1-6 alkyl) , an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted carbocyclyl or optionally substituted heterocyclyl, wherein each of the C 1-6 alkyl is independently selected and optionally substituted;
  • R 102 at each occurrence is independently -OH, -OPg 1 , F, Cl, Br, I, C 1-4 alkyl optionally substituted with 1-3 fluorine, cyclopropyl, cyclobutyl, C 1-4 alkoxy optionally substituted with 1-3 fluorine, cyclopropoxy, or cyclobutoxy, wherein Pg 1 is an oxygen protecting group,
  • R 7 is isopropyl or an optionally substituted C 3-6 cycloalkyl, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 7 is -CONH 2 , -CONH (C 1-4 alkyl) , or -CON (C 1-4 alkyl) (C 1-4 alkyl) , wherein each of the C 1-4 alkyl is independently selected and optionally substituted, e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • R 7 is an optionally substituted 4-7 membered heterocyclyl (e.g., piperidinyl or tetrahydropyranyl) , e.g., with one or two substituents independently selected from C 1-4 alkyl optionally substituted with 1-3 fluorine, -OH, -OPg 1 , C 1-4 alkoxy optionally substituted with 1-3 fluorine, and halogen, wherein Pg 1 is an oxygen protecting group.
  • heterocyclyl e.g., piperidinyl or tetrahydropyranyl
  • R 4 is C 1-6 alkyl or C 3-6 cycloalkyl, each optionally substituted with 1-3 fluorines, or R 4 is hydrogen, -CN, -COOH, methyl, ethyl, cyclopropyl, isopropyl, or propyl.
  • a pharmaceutical composition comprising the compound of any one of embodiments 1-13 or a pharmaceutical salt thereof, and optionally a pharmaceutically acceptable carrier.
  • a method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1-13 or a pharmaceutical salt thereof, or the pharmaceutical composition of embodiment 14, wherein the disease or disorder is obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic steatohepatitis, fatty liver, non-alcoholic fatty liver disease, bone disease, thyroid axis alteration, atherosclerosis, a cardiovascular disorder, tachycardia, hyperkinetic behavior, hypothyroidism, goiter, attention deficit hyperactivity disorder, learning disabilities, mental retardation, hearing loss, delayed bone age, neurologic or psychiatric disease, thyroid cancer, or a combination thereof.
  • the disease or disorder is obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic steatohepatitis, fatty liver, non-alcoholic fatty liver disease, bone disease, thyroid axis alteration, atherosclerosis, a cardiovascular disorder, tachycardia, hyperkinetic behavior
  • a method of treating a liver disease or disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1-13 or a pharmaceutical salt thereof, or the pharmaceutical composition of embodiment 14.
  • liver disease or disorder is non-alcoholic steatohepatitis.
  • liver disease or disorder is non-alcoholic fatty liver disease.
  • a method of treating a lipid disease or disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1-13 or a pharmaceutical salt thereof, or the pharmaceutical composition of embodiment 14.
  • lipid disease or disorder is hyperlipidemia and/or hypercholesterolemia.
  • variable moiety herein can be the same or different as another specific embodiment having the same identifier.
  • Suitable groups for Het, A, R 1 , R 1’ , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 100 , R 102 , n and p in compounds of Formula I, II, or III, or subformula thereof, as applicable, are independently selected.
  • the described embodiments of the present invention can be combined. Such combination is contemplated and within the scope of the present invention.
  • any of Het, A, R 1 , R 1’ , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 100 , R 102 , n and p can be combined with embodiments defined for any other of Het, A, R 1 , R 1’ , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 100 , R 102 , n and p, as applicable.
  • Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers.
  • the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
  • Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
  • HPLC high performance liquid chromatography
  • C 1–6 is intended to encompass, C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1–6 , C 1–5 , C 1–4 , C 1–3 , C 1–2 , C 2–6 , C 2–5 , C 2–4 , C 2–3 , C 3–6 , C 3–5 , C 3–4 , C 4–6 , C 4–5 , and C 5–6 .
  • the term “compound (s) of the present disclosure” or “compound (s) of the present invention” refers to any of the compounds described herein according to Formula I (e.g., Formula I-1, Formula I-2, Formula I-3, Formula I-4) , Formula II (e.g., Formula II-1) , Formula III (e.g., Formula III-1, Formula III-2, Formula III-3, Formula III-4, any subformula thereof) , Formula I-X, Formula II-X, or Formula III-X, or any of Compounds 1-99, isotopically labeled compound (s) thereof (such as a deuterated analog wherein one of the hydrogen atoms is substituted with a deuterium atom with an abundance above its natural abundance) , possible stereoisomers thereof (including diastereoisomers, enantiomers, and racemic mixtures) , tautomers thereof, conformational isomers thereof, and/or pharmaceutically acceptable salts thereof (e.g., acid addition salt such as
  • Isotopes can be radioactive or non-radioactive isotopes.
  • Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 32 P, 35 S, 18 F, 36 Cl, and 125 I.
  • Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention.
  • administering means providing the compound or a prodrug of the compound to the individual in need of treatment.
  • alkyl refers to a straight-or branched-chain aliphatic hydrocarbon.
  • the alkyl which can include one to twelve carbon atoms (i.e., C 1-12 alkyl) or the number of carbon atoms designated (i.e., a C 1 alkyl such as methyl, a C 2 alkyl such as ethyl, a C 3 alkyl such as propyl or isopropyl, etc. ) .
  • the alkyl group is a straight chain C 1-10 alkyl group.
  • the alkyl group is a branched chain C 3-10 alkyl group.
  • the alkyl group is a straight chain C 1-6 alkyl group. In another embodiment, the alkyl group is a branched chain C 3-6 alkyl group. In another embodiment, the alkyl group is a straight chain C 1-4 alkyl group.
  • a C 1-4 alkyl group as used herein refers to a group selected from methyl, ethyl, propyl (n-propyl) , isopropyl, butyl (n-butyl) , sec-butyl, tert-butyl, and iso-butyl.
  • C 1-4 alkyl group refers to the C 1-4 alkyl group as defined, optionally substituted with one or more permissible substituents as described herein.
  • alkylene as used by itself or as part of another group refers to a divalent radical derived from an alkyl group.
  • non-limiting straight chain alkylene groups include -CH 2 -CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 -, and the like.
  • alkenyl as used by itself or as part of another group refers to an alkyl group as defined above containing one, two or three carbon-to-carbon double bonds.
  • the alkenyl group is a C 2-6 alkenyl group.
  • the alkenyl group is a C 2-4 alkenyl group.
  • Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.
  • alkynyl refers to an alkyl group as defined above containing one to three carbon-to-carbon triple bonds. In one embodiment, the alkynyl has one carbon-carbon triple bond. In one embodiment, the alkynyl group is a C 2-6 alkynyl group. In another embodiment, the alkynyl group is a C 2-4 alkynyl group.
  • Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.
  • alkoxy as used by itself or as part of another group refers to a radical of the formula OR a1 , wherein R a1 is an alkyl.
  • cycloalkoxy as used by itself or as part of another group refers to a radical of the formula OR a1 , wherein R a1 is a cycloalkyl.
  • haloalkyl refers to an alkyl substituted with one or more fluorine, chlorine, bromine and/or iodine atoms.
  • the haloalkyl is an alkyl group substituted with one, two, or three fluorine atoms.
  • the haloalkyl group is a C 1-10 haloalkyl group.
  • the haloalkyl group is a C 1-6 haloalkyl group.
  • the haloalkyl group is a C 1-4 haloalkyl group.
  • Carbocyclyl or “carbocyclic” as used by itself or as part of another group refers to a radical of a non–aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms ( “C 3–10 carbocyclyl” ) and zero heteroatoms in the non–aromatic ring system.
  • the carbocyclyl group can be either monocyclic ( “monocyclic carbocyclyl” ) or contain a fused, bridged or spiro ring system such as a bicyclic system ( “bicyclic carbocyclyl” ) and can be saturated or can be partially unsaturated.
  • Carbocyclyl also includes ring systems wherein the carbocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclic ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system.
  • Non-limiting exemplary carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclopentenyl, and cyclohexenyl.
  • “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms ( “C 3–10 cycloalkyl” ) . In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ( “C 3–8 cycloalkyl” ) . In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ( “C 3–6 cycloalkyl” ) . In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ( “C 5–6 cycloalkyl” ) . In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ( “C 5–10 cycloalkyl” ) .
  • Heterocyclyl or “heterocyclic” as used by itself or as part of another group refers to a radical of a 3–to 10–membered non–aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ( “3–10 membered heterocyclyl” ) .
  • the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • a heterocyclyl group can either be monocyclic ( “monocyclic heterocyclyl” ) or a fused, bridged, or spiro ring system, such as a bicyclic system ( “bicyclic heterocyclyl” ) , and can be saturated or can be partially unsaturated.
  • Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heterocyclyl also includes ring systems wherein the heterocyclic ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclic ring, or ring systems wherein the heterocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclic ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclic ring system.
  • Exemplary 3–membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiiranyl.
  • Exemplary 4–membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
  • Exemplary 5–membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl–2, 5–dione.
  • Exemplary 5–membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
  • Exemplary 5–membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
  • Exemplary 6–membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
  • Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
  • Exemplary 5-membered heterocyclyl groups fused to a C 6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
  • Exemplary 6-membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
  • Aryl as used by itself or as part of another group refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ( “C 6–14 aryl” ) .
  • an aryl group has six ring carbon atoms ( “C 6 aryl” ; e.g., phenyl) .
  • an aryl group has ten ring carbon atoms ( “C 10 aryl” ; e.g., naphthyl such as 1–naphthyl and 2–naphthyl) . In some embodiments, an aryl group has fourteen ring carbon atoms ( “C 14 aryl” ; e.g., anthracyl) .
  • Aryl also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
  • Alkyl as used by itself or as part of another group refers to an alkyl substituted with one or more aryl groups, preferably, substituted with one aryl group. Examples of aralkyl include benzyl, phenethyl, etc. When an aralkyl is said to be optionally substituted, either the alkyl portion or the aryl portion of the aralkyl can be optionally substituted.
  • Heteroaryl as used by itself or as part of another group refers to a radical of a 5–10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 pi electrons shared in a cyclic array) having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ( “5–10 membered heteroaryl” ) .
  • the point of attachment can be a carbon or nitrogen atom, as valency permits.
  • Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings.
  • Heteroaryl includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system.
  • Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
  • the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2–indolyl) or the ring that does not contain a heteroatom (e.g., 5–indolyl) .
  • Exemplary 5–membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl, and thiophenyl.
  • Exemplary 5–membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
  • Exemplary 5–membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
  • Exemplary 5–membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl.
  • Exemplary 6–membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl.
  • Exemplary 6–membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
  • Exemplary 6–membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
  • Exemplary 7–membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
  • Exemplary 5, 6–bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
  • Exemplary 6, 6–bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
  • Heteroaralkyl as used by itself or as part of another group refers to an alkyl substituted with one or more heteroaryl groups, preferably, substituted with one heteroaryl group. When a heteroaralkyl is said to be optionally substituted, either the alkyl portion or the heteroaryl portion of the heteroaralkyl can be optionally substituted.
  • alkylene, alkenylene, alkynylene, carbocyclylene, heterocyclylene, arylene, and heteroarylene refer to the corresponding divalent radicals of alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, respectively.
  • an “optionally substituted” group such as an optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl groups, refers to the respective group that is unsubstituted or substituted.
  • substituted means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
  • a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent can be the same or different at each position.
  • the optionally substituted groups herein can be substituted with 1-5 substituents.
  • Substituents can be a carbon atom substituent, a nitrogen atom substituent, an oxygen atom substituent or a sulfur atom substituent, as applicable.
  • each instance of R cc is, independently, selected from hydrogen, C 1–10 alkyl, C 1–10 haloalkyl, C 2–10 alkenyl, C 2–10 alkynyl, C 3–10 carbocyclyl, 3–14 membered heterocyclyl, C 6–14 aryl, and 5–14 membered heteroaryl, or two R cc groups are joined to form a 3–14 membered heterocyclyl or 5–14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R dd groups;
  • each instance of R ee is, independently, selected from C 1–6 alkyl, C 1–6 haloalkyl, C 2–6 alkenyl, C 2–6 alkynyl, C 3–10 carbocyclyl, C 6–10 aryl, 3–10 membered heterocyclyl, and 3–10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R gg groups; each instance of R ff is, independently, selected from hydrogen, C 1–6 alkyl, C 1–6 haloalkyl, C 2–6 alkenyl, C 2–6 alkynyl, C 3–10 carbocyclyl, 3–10 membered heterocyclyl, C 6–10 aryl and 5–10 membered heteroaryl, or two R ff groups are joined to form a 3–14 member
  • a “counterion” or “anionic counterion” is a negatively charged group associated with a positively charged group in order to maintain electronic neutrality.
  • An anionic counterion may be monovalent (i.e., including one formal negative charge) .
  • An anionic counterion may also be multivalent (i.e., including more than one formal negative charge) , such as divalent or trivalent.
  • Exemplary counterions include halide ions (e.g., F – , Cl – , Br – , I – ) , NO 3 – , ClO 4 – , OH – , H 2 PO 4 – , HSO 4 – , sulfonate ions (e.g., methansulfonate, trifluoromethanesulfonate, p–toluenesulfonate, benzenesulfonate, 10–camphor sulfonate, naphthalene–2–sulfonate, naphthalene–1–sulfonic acid–5–sulfonate, ethan–1–sulfonic acid–2–sulfonate, and the like) , carboxylate ions (e.g., acetate, propanoate, benzoate, glycerate, lactate, tartrate, glycolate, gluconate, and the like)
  • Exemplary counterions which may be multivalent include CO 3 2- , HPO 4 2- , PO 4 3- , B 4 O 7 2- , SO 4 2- , S 2 O 3 2- , carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like) , and carboranes.
  • carboxylate anions e.g., tartrate, citrate, fumarate, maleate, malate, malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate, azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and the like
  • Halo or “halogen” refers to fluorine (fluoro, –F) , chlorine (chloro, –Cl) , bromine (bromo, –Br) , or iodine (iodo, –I) .
  • Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms.
  • the substituent present on a nitrogen atom is a nitrogen protecting group (also referred to as an amino protecting group) .
  • Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated by reference herein.
  • the oxygen atom substituent present on an oxygen atom is an oxygen protecting group (also referred to as a hydroxyl protecting group) .
  • Oxygen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T.W. Greene and P.G.M. Wuts, 3 rd edition, John Wiley & Sons, 1999, incorporated herein by reference.
  • oxygen protecting groups include, but are not limited to, alkyl ethers or substituted alkyl ethers such as methyl, allyl, benzyl, substituted benzyls such as 4-methoxybenzyl, methoxylmethyl (MOM) , benzyloxymethyl (BOM) , 2–methoxyethoxymethyl (MEM) , etc., silyl ethers such as trymethylsilyl (TMS) , triethylsilyl (TES) , triisopropylsilyl (TIPS) , t-butyldimethylsilyl (TBDMS) , etc., acetals or ketals, such as tetrahydropyranyl (THP) , esters such as formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, etc., carbonates, sulfonates such as methane
  • leaving group is given its ordinary meaning in the art of synthetic organic chemistry and refers to an atom or a group capable of being displaced by a nucleophile. See, for example, Smith, March Advanced Organic Chemistry 6th ed. (501-502) .
  • Suitable leaving groups include, but are not limited to, halogen (such as F, Cl, Br, or I (iodine) ) , alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy) , arylcarbonyloxy, aryloxy, methoxy, N, O-dimethylhydroxylamino, pixyl, and haloformates.
  • halogen such as F, Cl, Br, or I (iodine)
  • pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art.
  • tautomers or “tautomeric” refers to two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa) .
  • the exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Tautomerizations (i.e., the reaction providing a tautomeric pair) may catalyzed by acid or base.
  • Exemplary tautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim, enamine-to-imine, and enamine-to- (adifferent enamine) tautomerizations.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • the terms “treat, “ “treating, “ “treatment, “ and the like refer to eliminating, reducing, or ameliorating a disease or condition, and/or symptoms associated therewith. Although not precluded, treating a disease or condition does not require that the disease, condition, or symptoms associated therewith be completely eliminated.
  • the terms “treat, “ “treating, “ “treatment, “ and the like may include “prophylactic treatment, “ which refers to reducing the probability of redeveloping a disease or condition, or of a recurrence of a previously-controlled disease or condition, in a subject who does not have, but is at risk of or is susceptible to, redeveloping a disease or condition or a recurrence of the disease or condition.
  • the term “treat” and synonyms contemplate administering a therapeutically effective amount of a compound described herein to a subject in need of such treatment.
  • the various starting materials, intermediates, and compounds of the preferred embodiments can be isolated and purified where appropriate using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Characterization of these compounds can be performed using conventional methods such as by melting point, mass spectrum, nuclear magnetic resonance, and various other spectroscopic analyses. Exemplary embodiments of steps for performing the synthesis of products described herein are described in greater detail infra.
  • Step 4 To a solution of 42-3 (140 mg, 0.47 mmol) in concentrated HCl (2.8 mL) and H 2 O (8 mL) was added a solution of NaNO 2 (37 mg, 0.53 mmol) in water (0.3 mL) slowly at 0°C.The resulting solution was stirred at 0°C for 1 hour. To a second flask was charged with ethyl N- (2-cyanoacetyl) carbamate (81 mg, 0.52 mmol) in pyridine (2.8 mL) and H 2 O (9.4 mL) , and the resulting solution was stirred at 0°C for 30 min. Then the first reaction mixture was filtered and transferred to the second one, and the resulting suspension was stirred at 0°Cfor 0.5 hour. The mixture was filtered and the filter cake was washed with water and petroleum ether, and dried to afford 42-4.
  • Step 5 To a 50 mL flask was charged with 42-4 (100 mg, 0.22 mmol) , potassium acetate (24 mg, 0.25 mmol) and DMA (3 mL) . The resulting solution was heated at 120°C for 3 hours. The reaction mixture was cooled to room temperature, and then purified by a prep-HPLC (aqueous NH 4 HCO 3 (10 mmol/L) /acetonitrile (21%-38%) ) to afford compound 42 (42 mg) .
  • a prep-HPLC aqueous NH 4 HCO 3 (10 mmol/L) /acetonitrile (21%-38%)
  • Step 2 To a stirred solution of 43-1 (2.02 g, 10.7 mmol) in DMSO (20 mL) in a 100 mL 3-necked round-bottom flask was added N- (3, 5-difluoro-4-hydroxyphenyl) acetamide (2.0 g, 10.7 mmol) , CuI (3.46 g, 18.2 mmol) and K 2 CO 3 (4.43 g, 32.1 mmol) at room temperature under nitrogen. The resulting mixture was stirred at 85°C for 16 hours. The mixture was cooled to room temperature and filtered. The filtrate was diluted with water and extracted with ethyl acetate.
  • Step 2 To a stirred solution of 44-1 in acetonitrile (100 mL) was added Selectfluor (2.24 g, 6.33 mmol) in portions at 0°C under nitrogen atmosphere. The mixture was stirred at 0°Cfor 10 min and then at 40°C for 40 min. The mixture was cooled to room temperature, quenched with a saturated aqueous NaHCO 3 solution, and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography to afford 44-2.
  • Step 2 To a 50 mL flask was charged with 41-1 (1.4 g, 6.31 mmol) , Zn power (2.06 g, 31.53 mmol) , NH 4 Cl (2.70 g, 50.45 mmol) in EtOH (14 mL) and H 2 O (7 mL) . The resulting mixture was stirred at room temperature for 16 hours, filtered, and the filtrate was extracted with ethyl acetate. The combined organic layer was concentrated to afford 41-2.
  • Step 3 To a solution of 35-2 (407 mg, 1.3 mmol) in water (8 mL) and concentrated hydrochloride acid (4 mL) was added sodium nitrite (90 mg, 1.3 mmol) at 0°C, and the mixture was stirred for 0.5 hour. To above mixture was added a solution of stannous chloride (983 mg, 5.2 mmol) in concentrated hydrochloride acid (2 mL) . The reaction mixture was then stirred for 0.5 hour and filtered. The filter cake was collected to afford 35-3 which was used for next step without further purification.
  • Step 4 To a solution of 35-3 (700 mg, 1.3 mmol) in ethanol (5 mL) and water (15 mL) was added pyruvic acid (229 mg, 2.6 mmol) at room temperature. The mixture was stirred for 0.5 hour and filtered. The filter cake was washed with water, collected, and slurried with dichloromethane (15 mL) . The slurry was filtered, and the filter cake was collected and dried to afford 35-4.
  • Step 6 To a solution of 35-5 (55 mg, 0.12 mmol) in dimethylacetamide (3 mL) was added potassium acetate (59 mg, 0.6 mmol) at room temperature. The mixture was stirred at 60°C for 16 hours, cooled, and purified by a prep-HPLC (acetonitrile with 0.05%TFA in water: 25%to 95%) to afford 35.
  • Step 1 To a suspension of 3, 6-dichloropyridazine (10.43 g, 70.0 mmol) in water (210 mL) was added concentrated sulfuric acid (5.74 mL, 105.0 mmol) , silver nitrate (1.19 g, 7.0 mmol) and cyclopropanecarboxylic acid (7.24 mL, 91.0 mmol) at room temperature. The mixture was heated to 65°C, and a solution of ammonium persulfate (23.94 g, 105.0 mmol) in water (70 mL) was added dropwise over 20 mins. (T ⁇ 72°C) .
  • Step 1 A mixture of 4-amino-2, 6-dichlorophenol (18.2 g, 102 mmol) , 3, 6-dichloropyridazine (15 g, 100 mmol) and cesium carbonate (37 g, 115 mmol) in N, N-dimethylacetamide (100 mL) was stirred at 110°C for 3 hours and then at 70°C for 16 hours under nitrogen. After cooled to room temperature, the mixture was filtered with Celite, and the filtrate was poured into water (600 mL) and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford 25-1 which was used in the next step directly.
  • Step 2 To a solution of 25-1 (14 g, 38.6 mmol) in acetic acid (120 mL) was added benzoic anhydride (9.6 g, 42.5 mmol) , and the mixture was stirred at 100°C for 1 hour. After the reaction mixture was cooled to room temperature, sodium acetate (6.3 g, 77 mmol) was added and the mixture was stirred at 110°C for 16 hours. Water (120 mL) was added dropwise after the mixture was cooled to 70°C, and the mixture was then cooled to room temperature and filtered. The filter cake was washed with water, and recrystallized with AcOH (220 mL) and water (200 mL) to afford 25-2.
  • benzoic anhydride 9.6 g, 42.5 mmol
  • Step 2 To a stirred solution of 45-1 (16 g, 94.0 mmol) in tetrahydrofuran (160 mL) was added n-BuLi (1.6 M in hexane, 70 mL, 112.9 mmol) dropwise at -78°C under nitrogen, and the mixture was stirred at -78°C for 2 hours. MeI (17.4 g, 122.2 mmol) was added dropwise at -78°C, and the mixture was allowed to warm to room temperature and stirred for 16 hours. The mixture was quenched with a saturated aqueous NH 4 Cl solution and extracted with ethyl acetate.
  • Step 3 To a stirred solution of 45-2 (21 g, 114.0 mmol) in MeOH (200 mL) was added concentrated HCl (4.50 mL) dropwise. The mixture was stirred at 50°C for 3 hours and concentrated. The residue was purified by flash column chromatography on silica gel (petroleum ether) to afford 45-3.
  • Step 1 To a 50 mL flask was added 35-3 (600 mg, 1.21 mmol) , 2-oxobutanoic acid (247 mg, 2.42 mmol) , EtOH (5 mL) and H 2 O (15 mL) at room temperature. The resulting mixture was stirred at room temperature for 1 hour and filtered. The filter cake was washed with water, collected, and diluted with dichloromethane. The slurry was stirred, filtered and the filter cake was dried to afford 37-1.
  • Step 1 To a suspension of 3, 6-dichloropyridazine (10.0 g, 67.56 mmol) in water (200 mL) was added concentrated sulfuric acid (5.5 ml, 101.36 mmol) , silver nitrate (1.15 g, 6.76 mmol) and 2-ethylbutanoic acid (10.2 g, 87.84 mmol) at room temperature. The mixture was heated to 65°C, and a solution of ammonium persulfate (23.2 g, 101.36 mmol) in water (70 mL) was added dropwise over 20 mins (T ⁇ 72°C) .
  • the mixture was stirred at 70°C for 0.5 hour, cooled to room temperature, and poured into ice-water.
  • the combined organic layer was washed with an aqueous sodium hydroxide (1 M) solution, water and brine.
  • the separated organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to afford 40-1 which was used for next step without further purification.
  • Step 2 To a solution of 40-1 (5.0 g, 22.94 mmol) in dimethylacetamide (50 mL) was added cesium carbonate (7.8 g, 23.98 mmol) and 4-amino-2, 6-dichlorophenol (3.7 g, 20.85 mmol) at room temperature. The mixture was stirred at 90°C for 6 hours under nitrogen. After cooled to room temperature, the reaction mixture was diluted with ethyl acetate, and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated.
  • Step 1 To a suspension of 3, 6-dichloropyridazine (12.5 g, 84 mmol) in water (160 mL) was added concentrated sulfuric acid (12.6 g, 126 mmol) , silver nitrate (1.4 g, 8.4 mmol) and 2-phenylacetic acid (15 g, 110 mmol) at room temperature. The mixture was heated to 65°C, and a solution of ammonium persulfate (28 g, 126 mmol) in water (100 mL) was added dropwise over 20 mins (T ⁇ 72°C) . After stirring at 70°C for 0.5 hour, the reaction mixture was cooled to 0°C and separated.
  • Step 1 To a solution of 3, 6-dichloropyridazine (10 g, 67 mmol) in acetonitrile (150 mL) and water (150 mL) was added 3-oxocyclobutane-1-carboxylic acid (23 g, 201 mmol) , ammonium persulfate (30.6 g, 134 mmol) , silver nitrate (11.4 g, 67 mmol) and trifluoroacetic acid (1.5 g, 13.4 mmol) at room temperature. The reaction mixture was stirred at 70°C for 2 hours under nitrogen atmosphere. The mixture was cooled and filtered.
  • Step 2 To a solution of 16-1 (560 mg, 2.6 mmol) in methanol (10 mL) was added potassium borohydride (180 mg, 3.4 mmol) at 0°C under nitrogen. The mixture was stirred at 0°C for 1 hour, followed by quenching with water. The mixture was extracted with ethyl acetate, and the organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to afford 16-2.
  • potassium borohydride 180 mg, 3.4 mmol
  • Step 1 To a solution of 34-1 (20 mg, 0.04 mmol) in dichloromethane (10 mL) was added boron tribromide (0.5 mL) at 0°C. The mixture was stirred at 0°C for 2 hours, and then poured into ice water (10 mL) . A saturated aqueous sodium bicarbonate solution was added, and the mixture was extracted with dichloromethane. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by a prep-HPLC (acetonitrile with 0.05%of aqueous trifluoroacetic acid: 20%to 95%) to afford 34.
  • Step 1 To a 20 mL sealed tube purged with nitrogen was charged with 4-bromo-1, 2, 3, 6-tetrahydropyridazine-3, 6-dione (500 mg, 2.62 mmol) , 1- [4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) -1, 2, 3, 6-tetrahydropyridin-1-yl] ethan-1-one (789 mg, 3.142 mmol) , K 2 CO 3 (729 mg, 5.24 mmol) , 1, 2-dimethoxyethane (8 mL) , H 2 O (2 mL) and Pd (dtbpf) Cl 2 (171 mg, 0.26 mmol) .
  • reaction mixture was irradiated under microwave at 100°C for 1 hour.
  • the mixture was cooled to room temperature, filtered, and concentrated.
  • the residue was purified by a reversed phase column chromatography with 0.1%of aqueous formic acid -acetonitrile (20%to 40%gradient in 5 min. ) to afford 19-1.
  • Step 2 To a 250 mL flask purged with nitrogen was charged with 19-1 (1.0 g, 4.25 mmol) , 10%Pd/C (150 mg, 1.41 mmol) and NMP (60 mL) . The resulting mixture was stirred under H 2 atmosphere at room temperature for 2 hours. The mixture was filtered and the filtrate was concentrated to afford 19-2.
  • Step 3 To a solution of 47-2 (3.00 g, 12.42 mmol) and NH 4 Cl (6.64 g, 124.20 mmol) in H 2 O (15 mL) and EtOH (30 mL) was added Zn powder (4.06 g, 62.10 mmol) . The resulting mixture was stirred at room temperature overnight followed by filtration. The filtrate was extracted with ethyl acetate and the combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford 47-3 which was used in next step without further purification.
  • Step 4 A solution of 47-3 (1.40 g, 6.62 mmol) in Ac 2 O (10 mL) was heated at 100°C for 2 hours. Then the reaction mixture was cooled to room temperature followed by quenching with water (50 mL) . The resulting solution was extracted with ethyl acetate, and the combined organic layer was washed with saturated aqueous NaHCO 3 solution, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford 47-4 which was used in next step without further purification.
  • Step 5 To a solution of 47-4 (1.40 g, 4.74 mmol) in THF (14 mL) and H 2 O (7 mL) was added LiOH . H 2 O (0.40 g, 9.471 mmol) . The resulting solution was stirred at room temperature for 2 hours, followed by diluting with water. The mixture was extracted with ethyl acetate, and the combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford 47-5 which was used in next step without further purification.
  • Step 1 To a solution of 4- (benzyloxy) phenylhydrazine (10.0 g, 46.67 mmol) and 3-methylbutanal (4.02 g, 46.67 mmol) in EtOH (100 mL) was added 1%H 2 SO 4 (66 mL) dropwise at 0°C under nitrogen atmosphere. The mixture was stirred at 80°C for 3 hours and then cooled to room temperature. The mixture was partially concentrated under reduced pressure, and then extracted with ethyl acetate. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography with ethyl acetate/petroleum ether (1/8) to afford 56-1.
  • Step 2 To a solution of 56-1 (4.0 g, 15.07 mmol) in MeOH (120 mL) was added 10%Pd/C (0.4 g) under nitrogen atmosphere. The resulting mixture was stirred under H 2 atmosphere at room temperature for 16 hour, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with ethyl acetate/petroleum ether (1: 3) to afford 56-2.
  • Step 3 To a solution of 56-2 (322 mg, 1.84 mmol) in DMSO (3.2 mL) was added 1, 3-dichloro-2-fluoro-5-nitrobenzene (425 mg, 2.02 mmol) and K 2 CO 3 (508 mg, 3.68 mmol) at room temperature. The mixture was heated at 125°C under nitrogen atmosphere for 2 hours. The resulting mixture was then cooled to room temperature and filtered. The filtrated was diluted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography with ethyl acetate/petroleum ether (1: 50) to afford 56-3.
  • Step 4 To a solution of 56-3 (600 mg, 1.64 mmol) in toluene (6 mL) was added p-TsCl (376 mg, 1.97 mmol) in toluene (3 mL) , 50%aqueous KOH (6 mL) , and Bu 4 NHSO 4 (56 mg, 0.16 mmol) at 0°C. The mixture was allowed to warm to room temperature and stirred for 16 hours, and water (25 mL) was added. The mixture was extracted with ethyl acetate, and the combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography ethyl acetate/petroleum ether (1: 60) to afford 56-4.
  • Step 5 To a suspension of 56-4 (1.07 g, 2.06 mmol) in EtOH (22 mL) and H 2 O (11 mL) was added NH 4 Cl (882 mg, 16.48 mmol) and iron powder (575 mg, 10.30 mmol) portion wise. The resulting mixture was stirred at 50°C under nitrogen atmosphere for 2 hours, cooled to room temperature and filtered. The filtrated was extracted with ethyl acetate, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel column chromatography with ethyl acetate/petroleum ether (1: 6) to afford 56-5.
  • Step 6 To a stirred solution of 56-6 (190 mg, 0.31 mmol) in THF (4 mL) was added TBAF (1 M in THF, 4.0 mL) in portions at room temperature under nitrogen atmosphere. The resulting mixture was heated at 65 °C under nitrogen atmosphere for 48 hours, followed by cooling and quenching with water (20 mL) . The resulting mixture was extracted with ethyl acetate, and the combined organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by a prep-HPLC with 0.05%aqueous NH 3 . H 2 O/acetonitrile to afford 56.
  • Step 1 To a suspension of 2, 6-dichloro-4-nitrophenol (41.6 g, 200 mmol) and potassium carbonate (110.4 g, 800 mmol) in dimethylformamide (200 mL) was added iodomethane (56.8 g, 400 mmol) at 0°C. The mixture was stirred at 60°C for 1.5 hours, followed by cooling to room temperature and quenching with water (1 L) . The resulting slurry was stirred for 10 minutes and filtered. The filter cake was washed with water and dried to afford 58-1.
  • Step 4 To a suspension of 3, 6-dichloropyridazine (455 mg, 3.0 mmol) , 2- (1- (tert-butoxycarbonyl) piperidin-4-yl) acetic acid (970 mg, 4.0 mmol) , silver nitrate (510 mg, 3.0 mmol) and trifluoroacetic acid (68 mg, 0.6 mmol) in acetonitrile (20 mL) and water (20 mL) was added a solution of ammonium persulfate (1.37 g, 6 mmol) at 65°C. Then the reaction mixture was heated at 75°C for 2 hours, followed by cooling to room temperature and neutralization with NH 3 . H 2 O.
  • Step 7 To a solution of 58-7 (50 mg, 0.084 mmol) in acetic acid (5 mL) was added sodium acetate (27 mg, 0.34 mmol) at room temperature, and the mixture was then heated at 100°C for overnight. After cooled to room temperature, the reaction mixture was poured into water and extracted with dichloromethane. The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to afford 58-8, which was used to the next step without further purification.
  • Step 1 To a solution of methyl 2- (4-hydroxyphenyl) acetate (5 g, 30 mmol) and diisobutylamine (388 mg, 3.0 mmol) in toluene (50 mL) was added a solution of sulfuryl dichloride (8.1 g, 60 mmol) in toluene (15 mL) dropwise at 70°C under N 2 atmosphere. The mixture was then stirred at 70°C for 1 hour, and poured into water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to afford 70-1.
  • Step 2 To a solution of 70-1 (4.9 g, 20.94 mmol) in tetrahydrofuran (100 mL) was added LiAlH 4 (8.4 mL, 2.5M in tetrahydrofuran, 20.94 mmol) dropwise at -10°C under N 2 atmosphere. The mixture was then stirred at -10°C for 15 minutes, followed by quenching with water and a 15%aqueous sodium hydroxide solution at 0°C. The mixture was diluted with ethyl acetate and filtered.
  • the filtered cake was rinsed with ethyl acetate and the filtrate was washed with aqueous hydrochloric acid (1N) , water (50 mL) and brine (50 mL) , dried over sodium sulfate, filtered and concentrated to afford 70-2.
  • Step 3 A mixture of 70-2 (2.75 g, 13.35 mmol) , 3, 6-dichloro-4- (propan-2-yl) pyridazine (3.06 g, 16.02 mmol) , potassium carbonate (3.68 g, 26.70 mmol) , and cuprous iodide (1.27 g, 6.68 mmol) in dimethyl sulfoxide (14 mL) was stirred at 90°C for 4 hours under N 2 atmosphere. Then the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated.
  • Step 6 To a solution of 70-5 (250 mg, 0.52 mmol) in acetic acid (2 mL) was added sodium acetate (255 mg, 3.11 mmol) at room temperature. The mixture was heated at 120°C for 16 hours, and then poured into water and filtered. The filtered cake was dried to afford 70-6.
  • Step 7 To a solution of 70-6 (190 mg, 0.41 mmol) in acetonitrile (3 mL) was added bromo (trimethyl) silane (0.5 mL) at room temperature. The mixture was heated at 70°Cfor 3 hours, and then poured into water and filtered. The filtered cake was purified by a prep-HPLC (acetonitrile with 0.05%TFA in water: 15%to 95%) to afford 70. LCMS (ESI, m/z) : 407.3 [M+H] + .
  • Step 1 To a solution of 27-1 (10.0 g, 41.82 mmol) in DMF (100 mL) was added NaH (60%in oil, 2.51 g, 62.74 mmol) in several batches at -5°C. To the mixture was added iodomethane (10.09 g, 71.10 mmol) drop wise at -5°C. The resulting solution was stirred at -5°C for 3 h, followed by quenching with NH 4 Cl (aq. ) . The mixture was extracted with ethyl acetate and the combined organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography on silica gel with ethyl acetate/petroleum ether (1: 10) to afford 71-1.
  • Step 1 To a solution of 74-1 (1.6 g, 4 mmol) in acetic acid (20 mL) was added sodium acetate (1.64 g, 20 mmol) at room temperature. The mixture was heated at 120°C for 8 hours, and then poured into water and filtered. The filtered cake was washed with water and dried to afford 74-2.
  • Step 2 To a suspension of 74-2 (305 mg, 0.8 mmol) in acetic acid (20 mL) was added zinc powder (780 mg, 12 mmol) . Then the mixture was heated at 85°C for 48 hours under N 2 atmosphere. After cooled to room temperature, the reaction mixture was diluted with water, and extracted with dichloromethane. The combined organic layer was dried over sodium sulfate, filtered and concentrated to afford 74-3.
  • Step 4 To a solution of 74-4 (25 mg, 0.05 mmol) in ethanol (30 mL) was added (diacetoxyiodo) benzene (32 mg, 0.1 mmol) at room temperature. The mixture was stirred for 24 hours, and then concentrated to a residue which was purified by a prep-HPLC (acetonitrile with 0.05%TFA in water: 12%to 95%) to afford 74. LCMS (ESI, m/z) : 473.3 [M+H] + .
  • Step 1 To a suspension of 25-2 (4.5 g, 12 mmol) in acetic acid (150 mL) was added zinc powder (4.6 g, 70 mmol) . The mixture was then heated to 80°C for 3 hours. After cooled to room temperature, the reaction mixture was diluted with ethyl acetate, and the organic layer was washed with water, an aqueous NaHCO 3 solution and brine, and then dried over sodium sulfate, filtered and concentrated to afford 73-1.
  • Step 1 A solution of 2, 6-dichloro-4-nitro-phenol (10.0 g, 48 mmol) in N, N-dimethylformamide (200 mL) at 25°C was treated with 1, 4-diazabicyclo [2.2.2] octane (10.0 g, 96 mmol) and dimethylthiocarbamoyl chloride (9.5 g, 76 mmol) . The reaction was stirred at 25°C for18 hours. Then the mixture was diluted with ethyl acetate, washed with aqueous hydrochloric acid, water and brine, dried over magnesium sulfate, filtered and concentrated. The residue was purified with chromatography on silica gel to afford 80-1.
  • Step 2 Neat 80-1 (6.6 g, 23 mmol) was heated to 180-200°C for 20 min. and then cooled to afford 80-2.
  • Step 1 To a solution of (4-methoxy-2, 6-dimethylphenyl) methanol (1.0 g, 6.0 mmol) in ether (15 mL) was added dropwise a solution of phosphorus tribromide (1.9 g, 7.2 mmol) in ether (2 mL) at 0°C. The mixture was stirred at 0°C to room temperature for 40 min, followed by quenching with a saturated aqueous sodium bicarbonate solution. The mixture was extracted with ethyl acetate, and the organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to afford 85-1.
  • Step 6 To a solution of 85-5 (20 mg, 0.05 mmol) in acetonitrile (5 mL) was added dropwise bromotrimethylsilane (0.5 mL) , and the reaction mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated and the residue was purified by a prep-HPLC (acetonitrile with 0.05%TFA in water: 25%to 50%) to afford 85. LCMS (ESI, m/z) : 367.3 [M+H] + .
  • Step 3 To a solution of 84-2 (1.0 g, 4.85 mmol) in dry dichloromethane (20 mL) was added dropwise triethylsilane (1.69 g, 14.53 mmol) and trifluoroacetic acid (2.76 g, 24.21 mmol) at 0°C. The mixture was stirred at room temperature overnight, followed by pouring into ice water. The mixture was neutralized to pH 4 to 5 with saturated sodium bicarbonate solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography on silica gel (3 %to 10 %ethyl acetate in petroleum ether) to afford 84-3.
  • Step 5 To a solution of 84-4 (980 mg, 2.85 mmol) in DCM (20 mL) was added BBr 3 (1.0M in DCM, 5.38 mL) drop wise at 0°C. The mixture was stirred at 0°C for 1.5 hour, followed by quenching with a saturated aqueous NaHCO 3 solution. The mixture was extracted with EtOAc and the combined organic layer was washed with brine, dried over Na 2 SO 4 , filtered and concentrated to afford 84-5.
  • Step 8 A mixture of 84-8 (100 mg, 0.16 mmol) and TBAF (1M in THF, 0.8 mL, 0.80 mmol) in THF (6 mL) was heated at 65°C overnight under nitrogen atmosphere. The mixture was diluted with water and extracted with EtOAc. The combined organic layer was dried over anhydrous Na 2 SO 4 , filtered and concentrated. The residue was purified by a prep-TLC (ethyl acetate) to afford crude product which was purified with a prep-HPLC to afford 84. LCMS (ESI, m/z) : 457.2 [M+H] + .
  • Step 2 A solution of 86-1 (70 mg, 0.13 mmol) and 3-chloroperbenzoic acid (28 mg, 0.16 mmol) in dichloromethane (2 mL) was stirred for 2 hours at room temperature. Then the mixture was quenched with an aqueous sodium thiosulfate solution, diluted with water and extracted with dichloromethane/tetrahydrofuran (2: 1) . The combined organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated.
  • Step 4 To a solution of 90-3 (1.70 g, 9.49 mmol) in HCl (conc., 10mL) was added a solution of NaNO 2 (720 mg, 10.43 mmol) in H 2 O (5 mL) at 0°C. After stirring for 1 hour, a solution of SnCl 2 .2H 2 O (5.14 g, 22.77 mmol) in HCl (conc. 5 mL) was added, and the mixture was stirred at 0°C for 2 hours. Then the mixture was diluted with water and neutralized to pH 7 with a saturated aqueous NaHCO 3 solution.
  • thyroid hormone receptor ⁇ agonist compounds as described herein can be prepared following similar methods and techniques herein. Characterization of the compounds are provided in Table 1 below:
  • TR-FRET binding assay was used to test representative compounds herein.
  • the ligand binding domain of thyroid hormone receptor alpha and the ligand binding domain of thyroid hormone receptor beta with GST tag were purchased from Invitrogen.
  • Biotin-SRC2-2 coactivator peptide was purchased from Sangon Biotech, Europium anti-GST and Streptavidin-D2 was from Cisbio.
  • TR ⁇ -LBD or TR ⁇ -LBD coding sequence was inserted into pBIND expression vector (Promega, E1581) to express TR ⁇ -GAL4 binding domain chimeric receptors.
  • This expression vector was transfected into HEK293-LUC host cells with reporter vector (pGL4.35 which carry a stably integrated GAL4 promoter driven luciferase reporter gene) .
  • reporter vector pGL4.35 which carry a stably integrated GAL4 promoter driven luciferase reporter gene
  • 75 nL compound was added into 384 well assay plate using ECHO550 and then add HEK293-LUC cells (transfected, 17,000 cells/well) into the plate using phenol red-free DMEM containing 5%charcoal/dextran-treated FBS and incubated for 16-20 h at 37 °Cunder 5%CO 2 atmosphere.
  • Compound TR ⁇ EC 50 ( ⁇ M) Compound TR ⁇ EC 50 ( ⁇ M) MGL-3196 4.0 37 1.22 1 7.10 40 0.61 2 9.88 46 0.09 3 8.93 47 4.13 4 12.17 56 1.05 7 7.38 60 1.19 8 2.10 62 5.29 9 0.64 63 8.43 11 0.70 65 4.10 14 0.65 66 1.90 15 4.61 71 0.46 17 12.20 73 11.23 18 0.35 75 0.27 20 4.98 83 0.23 22 0.20 90 2.76 23 0.18 91 4.35 25 12.45 92 13.62 27 0.77 98 5.5 33 11.51 99 18.5
  • Thawing media used in the study consists of: 31 mL Williams E medium (GIBCO Cat# 12551-032) ; 15 mL isotonic percoll (GE Healthcare Cat# 17-0891-09) ; 500 uL 100XGlutaMax (GIBCO Cat# 35050) ; 750 uL HEPES (GIBCO Cat# 15630-080) ; 2.5 mL FBS (Corning Cat# 35-076-CVR) ; 50 uL human insulin (GIBCO Cat# 12585-014) and 5 uL dexamethasone (NICPBP) . Incubation media is made of Williams E medium supplemented with 1xGlutaMax.
  • thawing medium and incubation medium were placed in a 37°C water bath for at least 15 minutes prior to use.
  • Compound stock solutions were diluted to 100 ⁇ M by combining 198 ⁇ L of 50%acetonitrile/50%water and 2 ⁇ L of 10 mM stock solution. Verapamil was use as a positive control in the assay.
  • Vials of cryopreserved hepatocytes were removed from storage and thawed in a 37°C water bath with gentle shaking. Contents of the vial were poured into the 50 mL thawing medium conical tube. Vials were centrifuged at 100 g for 10 minutes at room temperature.
  • hepatocytes were re-suspended with serum-free incubation medium to yield ⁇ 1.5 ⁇ 10 6 cells/mL. Hepatocyte viability and density were counted using a Trypan Blue exclusion, and then cells were diluted with serum-free incubation medium to a working cell density of 0.5 ⁇ 10 6 viable cells/mL. Then, a portion of the hepatocytes at 0.5 ⁇ 10 6 viable cells/mL was boiled for 5 minutes prior to adding to the plate as negative control to eliminate the enzymatic activity so that little or no substrate turnover should be observed. The boiled hepatocytes were used to prepare negative samples.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux agonistes du récepteur des hormones thyroïdiennes (TR), par exemple, représentés par la formule I, II ou III. L'invention concerne également des procédés de préparation de ces nouveaux agonistes du TR et un procédé d'utilisation de ces nouveaux agonistes du TR pour le traitement de maladies ou troubles modulés par des agonistes du TR, tels que la NAFLD, la NASH, le diabète, l'hyperlipidémie et/ou l'hypercholestérolémie.
PCT/CN2019/110494 2018-10-12 2019-10-11 Agonistes du récepteur des hormones thyroïdiennes WO2020073974A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020217013711A KR20210076932A (ko) 2018-10-12 2019-10-11 갑상선 호르몬 수용체 작용제
CN201980061525.7A CN112739692A (zh) 2018-10-12 2019-10-11 甲状腺激素受体激动剂
US17/284,149 US20210355110A1 (en) 2018-10-12 2019-10-11 Thyroid hormone receptor agonists
CA3113373A CA3113373A1 (fr) 2018-10-12 2019-10-11 Agonistes du recepteur des hormones thyroidiennes
AU2019359141A AU2019359141A1 (en) 2018-10-12 2019-10-11 Thyroid hormone receptor agonists
EP19871569.0A EP3864013A4 (fr) 2018-10-12 2019-10-11 Agonistes du récepteur des hormones thyroïdiennes
JP2021519839A JP2022504706A (ja) 2018-10-12 2019-10-11 甲状腺ホルモン受容体作動薬
IL282076A IL282076A (en) 2018-10-12 2021-04-05 Thyroid hormone receptor agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/109942 2018-10-12
CN2018109942 2018-10-12
CN2019075501 2019-02-20
CNPCT/CN2019/075501 2019-02-20

Publications (1)

Publication Number Publication Date
WO2020073974A1 true WO2020073974A1 (fr) 2020-04-16

Family

ID=70164457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/110494 WO2020073974A1 (fr) 2018-10-12 2019-10-11 Agonistes du récepteur des hormones thyroïdiennes

Country Status (9)

Country Link
US (1) US20210355110A1 (fr)
EP (1) EP3864013A4 (fr)
JP (1) JP2022504706A (fr)
KR (1) KR20210076932A (fr)
CN (1) CN112739692A (fr)
AU (1) AU2019359141A1 (fr)
CA (1) CA3113373A1 (fr)
IL (1) IL282076A (fr)
WO (1) WO2020073974A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240938A1 (fr) 2018-06-12 2019-12-19 Fronthera U.S. Pharmaceuticals Llc Agonistes du récepteur de l'hormone thyroïdienne et utilisations associées
US10800767B2 (en) 2018-08-24 2020-10-13 Terns, Inc. Thyroid hormone receptor beta agonist compounds
WO2020227549A1 (fr) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION
WO2020228577A1 (fr) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 Dérivé de pyridazinone et son utilisation
WO2021032161A1 (fr) * 2019-08-21 2021-02-25 成都海创药业有限公司 Composé de phénylate substitué par un halogène et utilisations associées
WO2021043185A1 (fr) * 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. Composé utilisé comme agoniste du récepteur bêta des hormones thyroïdiennes et son utilisation
WO2021104288A1 (fr) * 2019-11-26 2021-06-03 昆药集团股份有限公司 Composé de 1,2,4-triazine-3,5-dione, son procédé de préparation et son utilisation
US11034676B2 (en) 2018-12-13 2021-06-15 Terns, Inc. THRB receptor agonist compound and preparation method and use thereof
WO2021129465A1 (fr) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 Cristal de resmétirom, son procédé de préparation et ses utilisations
CN113248454A (zh) * 2021-07-06 2021-08-13 山东国邦药业有限公司 一种制备2-[苯基]-1,2,4-三嗪-3,5(2h,4h)-二酮类化合物的方法
CN113698388A (zh) * 2020-05-20 2021-11-26 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2021244582A1 (fr) * 2020-06-02 2021-12-09 成都康弘药业集团股份有限公司 NOUVEL AGONISTE DU RÉCEPTEUR β DE L'HORMONE THYROÏDIENNE
US11203587B2 (en) 2018-10-12 2021-12-21 Terns, Inc. Thyroid hormone receptor beta agonist compounds
WO2022037617A1 (fr) * 2020-08-19 2022-02-24 成都凡诺西生物医药科技有限公司 Dérivé de cyanotriazine, son procédé de préparation et son application
WO2022041026A1 (fr) * 2020-08-27 2022-03-03 InventisBio Co., Ltd. Composés de pyridazinone
WO2022068915A1 (fr) * 2020-09-30 2022-04-07 江苏恒瑞医药股份有限公司 Dérivé de 6-oxo-1,6-dihydropyridazine, son procédé de préparation et son application en médecine
WO2022087141A1 (fr) * 2020-10-23 2022-04-28 Madrigal Pharmaceuticals, Inc. Procédé de préparation de dérivés de 6-(4-nitro-phénoxy)-2h-pyridazin-3-one et de 6-(4-amino-phénoxy)-2h-pyridazin-3-one en tant qu'intermédiaires d'analogues des hormones thyroïdiennes
WO2022127779A1 (fr) * 2020-12-17 2022-06-23 山东第一医科大学(山东省医学科学院) Composé de pyridazinone substitué et son utilisation
WO2022127699A1 (fr) * 2020-12-15 2022-06-23 中国科学院上海药物研究所 COMPOSÉ AGONISTE SÉLECTIF DU RÉCEPTEUR β DES HORMONES THYROÏDIENNES, COMPOSITION PHARMACEUTIQUE ET SON UTILISATION
WO2022143574A1 (fr) 2020-12-30 2022-07-07 昆药集团股份有限公司 Dérivé de 2-pyridone, son procédé de préparation et son application pharmaceutique
WO2022171200A1 (fr) * 2021-02-10 2022-08-18 杭州领业医药科技有限公司 Forme cristalline de resmétirom, son procédé de préparation et son utilisation
WO2022184177A1 (fr) * 2021-03-04 2022-09-09 甫康（上海）健康科技有限责任公司 Composé aromatique, son procédé de préparation et son utilisation
WO2023020457A1 (fr) * 2021-08-17 2023-02-23 InventisBio Co., Ltd. Composés de pyridazinone ou pyridinone, leurs procédés de préparation et leurs utilisations
CN116606259A (zh) * 2023-07-19 2023-08-18 山东国邦药业有限公司 一种抗虫兽药沙咪珠利关键中间体的制备方法
US11986481B2 (en) 2012-09-17 2024-05-21 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7445996B2 (ja) * 2019-02-21 2024-03-08 ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用
TW202342457A (zh) * 2022-02-07 2023-11-01 大陸商四川海思科製藥有限公司 一種嗒𠯤酮衍生物製備方法及其中間物
CN115141109A (zh) * 2022-07-29 2022-10-04 浙江乾精新材料科技有限责任公司 一种氟铃脲关键中间体2,6-二氯-4-氨基苯酚的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471049A1 (fr) * 2002-01-30 2004-10-27 Kissei Pharmaceutical Co., Ltd. Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation
WO2007009913A1 (fr) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne
WO2009037172A1 (fr) * 2007-09-20 2009-03-26 F. Hoffmann-La Roche Ag Promédicaments pour analogues de l'hormone thyroïdienne
WO2014043706A1 (fr) * 2012-09-17 2014-03-20 Madrigal Pharmaceuticals, Inc. Procédé de synthèse d'analogues de l'hormone thyroïdienne et de ses polymorphes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111801324B (zh) * 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471049A1 (fr) * 2002-01-30 2004-10-27 Kissei Pharmaceutical Co., Ltd. Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation
WO2007009913A1 (fr) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone thyroidienne
WO2009037172A1 (fr) * 2007-09-20 2009-03-26 F. Hoffmann-La Roche Ag Promédicaments pour analogues de l'hormone thyroïdienne
WO2014043706A1 (fr) * 2012-09-17 2014-03-20 Madrigal Pharmaceuticals, Inc. Procédé de synthèse d'analogues de l'hormone thyroïdienne et de ses polymorphes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KELLY M.ET AL.: "Discovery of 2‑[3，5-Dichloro-4-(5-isopropyl-6-oxo-1，6-dihydropyridazin-3-yloxy)phenyl]-3，5-dioxo-2，3，4，5-tetrahydro[1，2，4]triazine-6-carbonitrile (MGL-3196)， a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, 8 April 2014 (2014-04-08), pages 3912 - 3923, XP055436939, DOI: 20191230165242 *
See also references of EP3864013A4 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11986481B2 (en) 2012-09-17 2024-05-21 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
WO2019240938A1 (fr) 2018-06-12 2019-12-19 Fronthera U.S. Pharmaceuticals Llc Agonistes du récepteur de l'hormone thyroïdienne et utilisations associées
US11964964B2 (en) 2018-06-12 2024-04-23 Xizang Haisco Pharmaceutical Co., Ltd. Thyroid hormone receptor agonists and uses thereof
US10800767B2 (en) 2018-08-24 2020-10-13 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US11203587B2 (en) 2018-10-12 2021-12-21 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US11084802B2 (en) 2018-12-13 2021-08-10 Terns, Inc. THRβ receptor agonist compound and preparation method and use thereof
US11034676B2 (en) 2018-12-13 2021-06-15 Terns, Inc. THRB receptor agonist compound and preparation method and use thereof
WO2020227549A1 (fr) * 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION
US11091467B2 (en) 2019-05-08 2021-08-17 Aligos Therapeutics, Inc. Modulators of THR-β and methods of use thereof
WO2020228577A1 (fr) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 Dérivé de pyridazinone et son utilisation
US11926618B2 (en) 2019-08-21 2024-03-12 Hinova Pharmaceuticals Inc. Halogen-substituted phenylate compound and applications thereof
EP4019510A4 (fr) * 2019-08-21 2023-01-25 Hinova Pharmaceuticals Inc. Composé de phénylate substitué par un halogène et utilisations associées
CN112409340A (zh) * 2019-08-21 2021-02-26 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
WO2021032161A1 (fr) * 2019-08-21 2021-02-25 成都海创药业有限公司 Composé de phénylate substitué par un halogène et utilisations associées
CN112409340B (zh) * 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
WO2021043185A1 (fr) * 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. Composé utilisé comme agoniste du récepteur bêta des hormones thyroïdiennes et son utilisation
WO2021104288A1 (fr) * 2019-11-26 2021-06-03 昆药集团股份有限公司 Composé de 1,2,4-triazine-3,5-dione, son procédé de préparation et son utilisation
WO2021129465A1 (fr) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 Cristal de resmétirom, son procédé de préparation et ses utilisations
CN114787153A (zh) * 2019-12-26 2022-07-22 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
CN113698388A (zh) * 2020-05-20 2021-11-26 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2021244582A1 (fr) * 2020-06-02 2021-12-09 成都康弘药业集团股份有限公司 NOUVEL AGONISTE DU RÉCEPTEUR β DE L'HORMONE THYROÏDIENNE
WO2022037617A1 (fr) * 2020-08-19 2022-02-24 成都凡诺西生物医药科技有限公司 Dérivé de cyanotriazine, son procédé de préparation et son application
WO2022041026A1 (fr) * 2020-08-27 2022-03-03 InventisBio Co., Ltd. Composés de pyridazinone
WO2022068915A1 (fr) * 2020-09-30 2022-04-07 江苏恒瑞医药股份有限公司 Dérivé de 6-oxo-1,6-dihydropyridazine, son procédé de préparation et son application en médecine
WO2022087141A1 (fr) * 2020-10-23 2022-04-28 Madrigal Pharmaceuticals, Inc. Procédé de préparation de dérivés de 6-(4-nitro-phénoxy)-2h-pyridazin-3-one et de 6-(4-amino-phénoxy)-2h-pyridazin-3-one en tant qu'intermédiaires d'analogues des hormones thyroïdiennes
WO2022127699A1 (fr) * 2020-12-15 2022-06-23 中国科学院上海药物研究所 COMPOSÉ AGONISTE SÉLECTIF DU RÉCEPTEUR β DES HORMONES THYROÏDIENNES, COMPOSITION PHARMACEUTIQUE ET SON UTILISATION
JP2023511222A (ja) * 2020-12-17 2023-03-16 山東第一医科大学（山東省医学科学院） 置換ピリダジノン類化合物とその用途
GB2608781B (en) * 2020-12-17 2023-07-05 Shandong First Medical Univ & Shandong Academy Of Medical Sciences Substituted pyridazinone compound and use thereof
US11964962B2 (en) 2020-12-17 2024-04-23 Shandong First Medical University & Shandong Academy Of Medical Sciences Substituted pyridazinone compound and use thereof
GB2608781A (en) * 2020-12-17 2023-01-11 Shandong First Medical Univ & Shandong Academy Of Medical Sciences Substituted pyridazinone compound and use thereof
WO2022127779A1 (fr) * 2020-12-17 2022-06-23 山东第一医科大学(山东省医学科学院) Composé de pyridazinone substitué et son utilisation
KR102651280B1 (ko) * 2020-12-17 2024-03-26 산동 퍼스트 메디컬 유니버시티 앤드 산동 아카데미 오브 메디컬 사이언시스 치환된 피리다진온류 화합물과 그 용도
AU2021402802B2 (en) * 2020-12-17 2023-11-23 Shandong First Medical University & Shandong Academy Of Medical Sciences Substituted pyridazinone compound and use thereof
KR20220143775A (ko) * 2020-12-17 2022-10-25 산동 퍼스트 메디컬 유니버시티 앤드 산동 아카데미 오브 메디컬 사이언시스 치환된 피리다진온류 화합물과 그 용도
WO2022143574A1 (fr) 2020-12-30 2022-07-07 昆药集团股份有限公司 Dérivé de 2-pyridone, son procédé de préparation et son application pharmaceutique
WO2022171200A1 (fr) * 2021-02-10 2022-08-18 杭州领业医药科技有限公司 Forme cristalline de resmétirom, son procédé de préparation et son utilisation
WO2022184177A1 (fr) * 2021-03-04 2022-09-09 甫康（上海）健康科技有限责任公司 Composé aromatique, son procédé de préparation et son utilisation
CN113248454B (zh) * 2021-07-06 2021-09-24 山东国邦药业有限公司 一种制备2-[苯基]-1,2,4-三嗪-3,5(2h,4h)-二酮类化合物的方法
CN113248454A (zh) * 2021-07-06 2021-08-13 山东国邦药业有限公司 一种制备2-[苯基]-1,2,4-三嗪-3,5(2h,4h)-二酮类化合物的方法
WO2023020457A1 (fr) * 2021-08-17 2023-02-23 InventisBio Co., Ltd. Composés de pyridazinone ou pyridinone, leurs procédés de préparation et leurs utilisations
CN116606259A (zh) * 2023-07-19 2023-08-18 山东国邦药业有限公司 一种抗虫兽药沙咪珠利关键中间体的制备方法
CN116606259B (zh) * 2023-07-19 2023-09-15 山东国邦药业有限公司 一种抗虫兽药沙咪珠利关键中间体的制备方法

Also Published As

Publication number Publication date
EP3864013A4 (fr) 2022-09-28
CN112739692A (zh) 2021-04-30
KR20210076932A (ko) 2021-06-24
CA3113373A1 (fr) 2020-04-16
AU2019359141A1 (en) 2021-04-22
US20210355110A1 (en) 2021-11-18
IL282076A (en) 2021-05-31
EP3864013A1 (fr) 2021-08-18
JP2022504706A (ja) 2022-01-13

Similar Documents

Publication Publication Date Title
WO2020073974A1 (fr) Agonistes du récepteur des hormones thyroïdiennes
JP6880127B2 (ja) 多環式カルバモイルピリドン化合物の合成
AU2016311426B2 (en) Compounds and compositions useful for treating disorders related to NTRK
AU2009226151B2 (en) Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
WO2021208963A1 (fr) Inhibiteur de bcl -2
WO2020258006A1 (fr) Composés hétérocycliques, leurs procédés de préparation et leurs méthodes d'utilisation
JPS6215555B2 (fr)
WO2017148357A1 (fr) Intermédiaire de sacubitril et procédé de préparation correspondant
CN113365992A (zh) 用于沃塞洛托的制备的方法和中间体
EP4267565A1 (fr) Composés hétéroaryles, leurs procédés de préparation et leurs utilisations
CN111099941B (zh) 一种烷基腈类化合物的制备方法
EP3737679B1 (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de la guanylate cyclase soluble
ES2451350T3 (es) Procedimientos para la preparación de compuestos de 2-(1-feniletil)isoindolin-1-ona
CN111517969A (zh) 地佐辛衍生物及其医药用途
TWI314932B (en) New synthesis of a camptothecin subunit
WO2022028317A1 (fr) Composés et compositions antidiabétiques
CN110650735A (zh) 通过钯-催化的分子内链烯基化的4,5-螺环的高度非对映选择性结构
SU1711674A3 (ru) Способ получени азонийспиронортропанолового сложного эфира
WO2023154842A1 (fr) Analogues du thr bêta et leurs utilisations
CN109096098A (zh) 一种反式-1,3-二羟基环丁烷-1-羧酸的制备方法
Kast et al. Functionally substituted vinyl carbanions, 43. Convenient transformation of hexopyranosides into α‐methylene δ‐lactone derivatives
WO2017190038A1 (fr) Analogues de la yohimbine et leurs utilisations
WO2009153897A1 (fr) Intermédiaire de synthèse de stémonamide et composition pharmaceutique pour la prévention et/ou le traitement du cancer
Lipińska et al. Structure-reactivity study of O-tosyl Cinchona alkaloids in their new synthesis and in hydrolysis to 9-epibases: unexpected formation of cinchonicine enol tosylate accelerated by microwave activation
WO2009093463A1 (fr) Inhibiteur de la mort cellulaire neuronale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19871569

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3113373

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021519839

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019359141

Country of ref document: AU

Date of ref document: 20191011

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217013711

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019871569

Country of ref document: EP

Effective date: 20210512